These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
37-1744899
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
1450 Centrepark Boulevard, Suite 210
West Palm Beach, Florida
|
33401
(Zip Code)
|
|
(Address of principal executive offices)
|
|
|
|
|
Title of Each Class
|
Name of Each Exchange on Which Registered
|
|
Common Stock, par value $0.01 per share
|
The New York Stock Exchange
|
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-Accelerated filer
o
|
Smaller reporting company
o
|
|
|
|
|
Emerging growth company
o
|
|
Glossary
|
Page
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
Terms
|
|
Definitions
|
|
Platform; Successor;
We; Us; Our; the Company
|
|
Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition.
|
|
Acquisitions
|
|
Agriphar Acquisition, Alent Acquisition, Arysta Acquisition, CAS Acquisition, MacDermid Acquisition, OMG Acquisition and OMG Malaysia Acquisition, collectively.
|
|
Agriphar
|
|
Percival S.A., a formerly Belgium
société anonyme
, and its agrochemical business, Agriphar.
|
|
Agriphar Acquisition
|
|
Acquisition of a 100% interest in Agriphar, completed on October 1, 2014.
|
|
AIs
|
|
Active ingredients.
|
|
Alent
|
|
Alent plc, a formerly public limited company registered in England and Wales.
|
|
Alent Acquisition
|
|
Acquisition of a 100% interest in Alent, completed on December 1, 2015 under the U.K. Companies Act 2006, as amended.
|
|
Amended and Restated
Credit Agreement
|
|
Platform's Second Amended and Restated Credit Agreement, dated as of August 6, 2014, among, inter alia, Platform, MacDermid Holdings, LLC, MacDermid, the subsidiaries of Platform and MacDermid Holdings, LLC from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent, as amended and restated from time to time.
|
|
Arysta
|
|
Arysta LifeScience Limited, formerly an Irish private limited company.
|
|
Arysta Acquisition
|
|
Acquisition of a 100% interest in Arysta, completed on February 13, 2015.
|
|
Arysta Seller
|
|
Nalozo, L.P., an affiliate of Nalozo S.à.r.l., a Luxembourg limited liability company and the original seller in the Arysta Acquisition.
|
|
ASC
|
|
Accounting Standard Codification.
|
|
ASU
|
|
Accounting Standards Update.
|
|
Board
|
|
Platform’s board of directors.
|
|
Bribery Act
|
|
The United Kingdom Bribery Act 2010.
|
|
CAS
|
|
Chemtura AgroSolutions business of Chemtura.
|
|
CAS Acquisition
|
|
Acquisition of a 100% interest in CAS, completed on November 3, 2014.
|
|
Chemtura
|
|
Chemtura Corporation, a Delaware corporation.
|
|
Credit Facilities
|
|
The First Lien Credit Facility and the Revolving Credit Facility, collectively, available under the Amended and Restated Credit Agreement.
|
|
EBITDA
|
|
Earnings before interest, taxes, depreciation and amortization.
|
|
ESPP
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan.
|
|
E.U.
|
|
European Union.
|
|
Exchange Act
|
|
Securities Exchange Act of 1934, as amended.
|
|
FASB
|
|
Financial Accounting Standard Board.
|
|
FCPA
|
|
Foreign Corrupt Practices Act of 1977.
|
|
February 2015 Notes Offering
|
|
Platform's private offering of $1.10 billion aggregate principal amount of 6.50% USD Notes due 2022 and €350 million aggregate principal amount of 6.00% EUR Notes due 2023, completed on February 2, 2015.
|
|
First Lien Credit Facility
|
|
First lien credit facility available under the Amended and Restated Credit Agreement.
|
|
Founder Entities
|
|
Mariposa Acquisition, LLC and Berggruen Holdings Ltd. and its affiliates, collectively.
|
|
GAAP
|
|
Generally Accepted Accounting Principles in the United States.
|
|
June 2015 Equity Offering
|
|
Platform's public offering of 18,226,414 shares of its common stock at a public offering price of $26.50 per share, which closed on June 29, 2015, raising gross proceeds of approximately $483 million.
|
|
MacDermid
|
|
MacDermid, Incorporated, a Connecticut corporation.
|
|
MacDermid Acquisition
|
|
Platform’s acquisition on October 31, 2013 of substantially all of the equity of MacDermid Holdings, LLC, which, at the time, owned approximately 97% of MacDermid. Platform acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement, dated October 25, 2013, between Platform and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan.
|
|
MacDermid Printing
|
|
MacDermid Printing Solutions LLC, now known as MacDermid Graphics Solutions LLC.
|
|
Terms
|
|
Definitions
|
|
November 2015 Notes Offering
|
|
Platform's private offering of $500 million aggregate principal amount of 10.375% USD Notes due 2021, completed on November 10, 2015.
|
|
NYSE
|
|
New York Stock Exchange.
|
|
OEM
|
|
Original Equipment Manufacturer.
|
|
OMG
|
|
OM Group, Inc. (NYSE:OMG), a Delaware corporation.
|
|
OMG Businesses
|
|
OMG's Electronic Chemicals and Photomasks businesses, collectively, other than their Malaysian subsidiary acquired separately.
|
|
OMG Acquisition
|
|
Platform's acquisition of the OMG Businesses completed on October 28, 2015.
|
|
OMG Malaysia
|
|
OMG Electronic Chemicals (M) Sdn Bhd, a subsidiary of OMG located in Malaysia, acquired separately by Platform in the OMG Malaysia Acquisition.
|
|
OMG Malaysia Acquisition
|
|
Platform's acquisition of 100% interest in OMG Malaysia completed on January 31, 2016.
|
|
PCAOB
|
|
Public Company Accounting Oversight Board.
|
|
PDH
|
|
Platform Delaware Holdings, Inc., a subsidiary of Platform.
|
|
PDH Common Stock
|
|
Shares of common stock of PDH.
|
|
Predecessor
|
|
MacDermid and its subsidiaries, collectively, for all periods prior to the MacDermid Acquisition.
|
|
Predecessor 2013 Period
|
|
Ten-month period from January 1, 2013 through October 31, 2013.
|
|
Prior Senior Notes
|
|
Platform's 6.00% EUR Notes due 2023 and 6.50% USD Notes due 2022, collectively.
|
|
Proposed Separation
|
|
Platform's proposed separation of its Agricultural Solutions and Performance Solutions businesses which we expect to complete in 2018.
|
|
Retaining Holder
|
|
Each Holder of an equity interest of MacDermid Holdings, LLC immediately prior to the closing of the MacDermid Acquisition, not owned by Platform, who executed a RHSA.
|
|
Revolving Credit
Facility
|
|
Revolving Credit Facility (in U.S. dollars or multicurrency) available under the Amended and Restated Credit Agreement.
|
|
RHSA
|
|
Retaining Holder Securityholders’ Agreement, dated as of October 31, 2013, entered into by and between Platform and each Retaining Holder pursuant to which they agreed to exchange their respective interests in MacDermid Holdings, LLC for shares of PDH Common Stock, at an exchange rate of $11.00 per share plus (i) a proportionate share of the $100 million contingent consideration and (ii) an interest in certain MacDermid pending litigation.
|
|
ROA
|
|
Return on assets.
|
|
RSUs
|
|
Restricted stock units issued by Platform from time to time under the 2013 Plan.
|
|
SEC
|
|
Securities and Exchange Commission.
|
|
Securities Act
|
|
Securities Act of 1933, as amended.
|
|
Senior Notes
|
|
Platform's 5.875% USD Notes due 2025, 6.00% EUR Notes due 2023 and 6.50% USD Notes due 2022, collectively.
|
|
September 2016 Equity Offering
|
|
Platform's public offering of 48,787,878 shares of its common stock at a public offering price of $8.25 per share, which closed on September 21, 2016, raising gross proceeds of approximately $402.5 million.
|
|
Series A Preferred Stock
|
|
Platform's 2,000,000 shares of Series A convertible preferred stock, which are convertible into shares of Platform’s common stock, on a one-for-one basis, at any time at the option of the Founder Entities.
|
|
Series B Convertible Preferred Stock
|
|
Platform's 600,000 shares of Series B convertible preferred stock issued to the Arysta Seller in connection with the Arysta Acquisition. At December 31, 2016, none of the Series B Convertible Preferred Stock remained outstanding.
|
|
SERP
|
|
Supplemental Executive Retirement Plan for executive officers of Platform.
|
|
Successor
|
|
Platform and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition.
|
|
Successor 2013 Period
|
|
Period from April 23, 2013 (inception) through December 31, 2013.
|
|
TCJA
|
|
Tax Cuts and Jobs Act of 2017.
|
|
USD Incremental Term Loan
|
|
Incremental term loan under the Incremental Amendment to the Amended and Restated Credit Agreement in an aggregate principal amount of $300 million used to finance the Agriphar Acquisition.
|
|
WACC
|
|
Weighted Average Cost of Capital.
|
|
Terms
|
|
Definitions
|
|
2013 Plan
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan.
|
|
2017 Annual Report
|
|
This annual report on Form 10-K for the fiscal year ended December 31, 2017.
|
|
2017 Notes Offerings
|
|
Platform's private offering of $550 million aggregate principal amount of 5.875% USD Notes due 2025, completed on November 24, 2017, and tack-on private offering of $250 million aggregate principal amount of additional 5.875% USD Notes due 2025, completed on December 8, 2017, collectively.
|
|
2018 Proxy Statement
|
|
Platform’s definitive proxy statement for its 2018 annual meeting of stockholders expected to be filed no later than 120 days after December 31, 2017.
|
|
5.875% USD Notes Indenture
|
|
The indenture, dated as of November 24, 2017, governing the 5.875% USD Notes due 2025.
|
|
5.875% USD Notes due 2025
|
|
Platform's 5.875% senior notes due 2023, denominated in U.S. dollars, issued in the 2017 Notes Offering.
|
|
6.00% EUR Notes due 2023
|
|
Platform’s 6.00% senior notes due 2023, denominated in euros, issued in the February 2015 Notes Offering.
|
|
6.50% USD Notes due 2022
|
|
Platform’s 6.50% senior notes due 2022, denominated in U.S. dollars, issued in the February 2015 Notes Offering.
|
|
10.375% USD Notes Indenture
|
|
The indenture, dated November 10, 2015, as amended from time to time, governing the 10.375% USD Notes due 2021.
|
|
10.375% USD Notes due 2021
|
|
Platform's 10.375% senior notes due 2021, denominated in U.S. dollars, issued in the November 2015 Notes Offering. As of December 31, 2017, none of the 10.375% USD Notes due 2021 remained outstanding.
|
|
Assembly Solutions
|
|||
|
|
Electronic Assembly Materials
|
|
Assembly Solutions focuses on the development, manufacture, and sale of innovative interconnect materials, primarily into the electronic market by providing specialized fluxes, solder spheres, organic encapsulants, and die attach materials that enable successful interconnection of semiconductor devices. We also offer metal reclaim systems, primarily for tin, used in electronic assembly.
|
|
|
Water Treatment
|
|
Fernox
is our water treatment product line used for the filtration and conditioning of water in residential boiler systems.
|
|
Electronic Solutions
|
|||
|
|
Plating
Products
|
|
Plating products are used to plate holes drilled through printed circuit boards to connect opposite sides of the board and the different layers of multi-layer printed circuit boards. Our key products include the
MacuSpec
,
M-Copper
and
M-System
.
|
|
|
Solderable
Finishes
|
|
Solderable finishing formulations are used to deposit coatings on printed circuit boards to preserve the solderability of the finished boards.
|
|
|
Circuit Formation Products
|
|
Circuit formation products represent an assortment of products for defining circuit patterns and bonding conductors to insulating materials.
|
|
|
Semiconductor Materials & Packaging
|
|
Our
Viaform
product family of copper damascene chemistry is used in semiconductor plating applications for creating conductors as narrow as 10 nanometers. Our
Microfab
family of plating chemistry is used in wafer level packaging applications, including copper pillar, redistribution layers (RDLs), nickel, tin bump, gold bump and thru-silicon via (TSV) applications.
|
|
|
Functional Conversion Coatings
|
|
Our products plate various parts that are used in automotive and aerospace equipment, appliances, computer hard disks and other electronic products.
|
|
Industrial Solutions
|
|||
|
|
Electroless
Nickel
|
|
Electroless nickel is applied to a variety of metal and plastic surfaces to enhance corrosion resistance, wear resistance, solderability (from Electronic Solutions), and to repair worn or over-machined surfaces in a variety of applications.
|
|
|
Plating
Products
|
|
The
CuMac
range of products for applications such as plating on aluminum wheels, plastic substrates and zinc-based die castings, and the
ChromKlad
and
ANKOR
range of hard chromium plating processes are utilized in various industrial finishing applications.
|
|
|
Pre-treatment and Cleaning Solutions
|
|
Pre-treatment and cleaning solutions are applied to prepare the surfaces of a wide variety of industrial products for additional treatment. We have a complete line of aqueous and semi-aqueous pre-treatment and cleaning products.
|
|
|
Functional Conversion Coatings
|
|
Functional conversion coatings are applied to metals to enhance corrosion resistance and paint adhesion in a wide spectrum of industrial applications where heavy duty usage and exposure to unfavorable environments are anticipated.
|
|
|
Hard-coated Films
|
|
Hard-coated films are used for the membrane switch in the touch screen applications.
|
|
Graphic Solutions
|
|||
|
|
Solid Sheet
Printing Elements
|
|
Solid sheet printing elements are digital and analog printing sheets, used in the flexographic printing and platemaking processes. Our extensive line of
Lux
flexographic plates are used in the commercial packaging letterpress newspaper and publication industries.
|
|
|
Liquid
Imaging
Products
|
|
Liquid products are liquid photopolymers used to produce printing plates for transferring images onto commercial packaging. Our key products are
MWH photopolymer
,
MWB 50 photopolymer
,
and M Stamp 40 photopolymer
. We also offer products that are used in the production of liquid photopolymer plates such as substrate, coverfilms and detergents.
|
|
Offshore Solutions
|
|||
|
|
Offshore
Fluids
|
|
Production fluids are used to operate valves for the deep water oil extraction and transportation process, and drilling fluids are used to operate valves for drilling rigs on the ocean floor. Production and drilling fluids are water-based hydraulic fluids used in subsea control systems.
|
|
Crop Protection
|
|
We are one of the largest Crop Protection chemical companies by revenue. Our diverse Crop Protection chemicals control biotic stresses, such as diseases (fungicides), weeds (herbicides) and insects (insecticides).
|
|
Fungicides
|
|
Fungicides prevent the spread of fungal diseases in crops. Our fungicides products include Evito, Fortix, Kasumin and Proplant.
|
|
Herbicides
|
|
Herbicides are used to control unwanted plants while leaving the targeted crops to grow unharmed. We offer total, non-selective and selective, herbicides with a variety of formulations for many temperate and tropical crops such as soybeans, corn, wheat, oil seed rape/canola, vegetables and sugar cane. Our main herbicide products are Dinamic, Everest, Pantera and Select.
|
|
Insecticides
|
|
Our insecticides, such as Cythrin Max, Orthene and Talisma, are products used against insect pests at different stages of the pest life cycle, from egg and larvae to nymph and adult. These products can have both crop and public health applications. Acaricides or miticides control a variety of mite pests on crops. These products are primarily targeted at tree fruit and nut, vine, ornamental and selected row crop applications for effective mite control programs. Our main miticide products, such as Acramite, Floramite and Omite, are sold globally.
|
|
BioSolutions
|
|
We believe we are have a strong position as innovator in BioSolutions and BioStimulants. These products are derived from natural sources that fall into several categories described below. This portfolio is highly differentiated through innovative technologies and mixtures and primarily protected by trade secrets.
|
|
BioStimulants
|
|
Biostimulants (biological stimulants) enhance crop vigor, yield and/or quality through physiological stimuli. Our BioStimulant products include Biozyme, BM Start and Appetizer.
|
|
Innovative Nutrition
|
|
Innovative nutrition products optimize the nutrition in plants by enhancing nutrient availability or use efficiency. Our Innovative Nutrition products include the Poliquel line.
|
|
BioControl
|
|
BioControl (biological control) products operate as conventional Crop Protection products with, in many cases, reduced residues of a synthetic origin. Our BioControl products, mainly biofungicides and bioinsecticides, include Ph-D, Carpovirusine, Vacciplant, Noctovi and a wide line of natural enemies and beneficial insects for Integrated Pest Management solutions in Japan.
|
|
Seed Treatment
|
|
Our diverse Seed Treatment portfolio encompasses products, such as Rancona and Vitavax. Our Seed Treatments are applied before planting by coating the seed in order to protect it during germination and the plant during its initial growth phases. We anticipate growth in Seed Treatments as a result of the increasing value of seeds and the use of higher-value GM seeds.
|
|
•
|
“Asset-Lite, High-Touch” Business Model.
Our businesses are evidenced by high margins and low capital expenditures which translates into high cash flow margins and returns on capital. Over
40%
of our employees are in either technological innovation or sales and services areas; hence “high-touch.” Our commitment to technological innovation and our extensive intellectual property portfolio enables us to develop our cutting-edge products. In order to continue to provide innovative products and highly specialized technical service to our customers, we place a premium on maintaining an expert and qualified employee base. Our business involves the formulation of a broad range of specialty chemicals, created by blending raw materials or developing new uses for existing AIs. This model allows us to conservatively manage our investments in fixed assets to both maintain and grow our businesses. Our existing fixed asset base is modern and well-maintained and, accordingly, requires low capital expenditures for maintenance.
|
|
•
|
Industry Leading Positions
.
Our businesses strategically focus on acquiring and maintaining leading positions in niche sectors of high-growth markets by offering high value-added services to our customers. We believe our scale and global reach in product development, marketing, and formulation provides us with advantages over many of our competitors, allowing us to maintain strong market share positions and drive profitable growth. Our strong market positions contribute to our ability to attract new customers and successfully enter new end-markets
.
|
|
•
|
Customer Driven Innovation and Partnerships.
We frequently work alongside our customers and other industry participants to develop new products and identify new market opportunities. We participate in a variety of dynamic end-markets where new unmet needs are always materializing. Our large sales and technical service teams provide continuous insights that help ensure our research and development efforts are appropriately focused. Customer requirements can lead to improved or uniquely tailored formulations of existing product offerings or to the development of completely new products to satisfy previously unmet needs. Tailoring products for specific OEMs or specific localized growing regions leads to sticky sales and significant customer switching costs. In our Agricultural Solutions business, we also frequently partner with molecule discovery focused companies to source new and complementary AIs for our portfolio. We believe these companies value our vast knowledge of local markets, regulations and distribution channels as they look to establish post-patent management strategies for their existing molecules.
|
|
•
|
Strong Expertise in Registration and Distribution
. Product registration is complex and crucial, particularly in the agrochemical space. Our Agricultural Solutions segment has a large team of specialists dedicated to the regulatory process across various jurisdictions, and we believe we are well-experienced in obtaining and defending the required registrations for our products in each country in which they are sold and for each crop on which they are applied. Once obtained, these registrations provide a right to use a product for a specified crop in that country or region for a number of years. In addition, our Agricultural Solutions segment has a strong network of distributors, which currently reaches over
100
countries and jurisdictions. Our large distribution network enables us to focus on profitable niche applications, which we believe are less sensitive to competitive pricing pressures. This distribution network, together with our geographical footprint, also allows us to attract licensing and resale opportunities from partner companies for new products, technologies, and applications.
|
|
•
|
Comprehensive Product Offering
. We provide our customers with a comprehensive offering of products that meet many of their specialty chemical needs. In many cases, we offer a full suite of products with complementary capabilities that provide a complete functional solution to the customer. We believe the ability to provide a “top-to-bottom” product offering is a significant competitive advantage over many of our smaller and regional competitors. We also believe that our existing product offerings offer many opportunities for growth in adjacent end-markets.
|
|
•
|
Performance-Driven Culture and Board with Proven Track Record
. We believe we have outstanding people who can deliver superior performance under the tutelage and oversight of proven and experienced leadership. Our culture is performance-focused and driven by empowering team members and then holding them accountable for their outcomes. We measure people on financial results, safety, customer satisfaction and commitments, legal compliance, and environmental stewardship. We measure our performance against benchmarks and drive operational excellence through continuous improvement. Our experienced management team is complemented by an experienced Board, which includes individuals with proven track records of successfully acquiring and managing businesses. Our business segments are also led by executives that have extensive experience in their respective fields.
|
|
•
|
Expand our Core Businesses.
We believe that we can capitalize on our existing capabilities to further enhance our technical capabilities, sophisticated process know-how, solutions orientation, strong customer relationships and deep industry knowledge. The Acquisitions enhanced the growth of each of our segments by extending their respective products breadth and expanding their international reach. We intend to further extend many of our product offerings through the development of new applications for our existing products or through synergistic combinations, and to target geographies with attractive market fundamentals where our strengths in marketing, portfolio development, regulation and customer education can add value for our customers.
|
|
•
|
Focused Investment in Product Innovation.
We place a strong emphasis on innovation. New products are developed and created by drawing upon our significant intellectual property portfolio and technical expertise. Building on our core competencies in product innovation, applications development, and technical services, we intend to drive organic
|
|
•
|
Leverage Customer Relationships.
We intend to continue to leverage our close customer relationships to execute our growth strategy by working directly with our customers to identify opportunities for new products. We also have strong collaborative relationships with OEMs who specify which specialty materials, chemistries, and technologies they need in their products. Working directly with our customers allows us to increase OEM qualification of our products and identify opportunities to grow with our customers. Such close customer relationships also provide a solid barrier to entry for competition.
|
|
•
|
Pursue Strategic Inorganic Growth
. Our founder, Martin E. Franklin and our Chief Executive Officer, Rakesh Sachdev have significant experience and expertise and have been highly successful in acquiring, integrating, and growing value-added businesses. We intend to pursue further inorganic initiatives as a way to enhance our growth and strategic position. We intend to focus primarily on businesses or assets within our existing end-markets that share our “Asset-Lite, High-Touch” philosophy, with product offerings that provide geographic or product complementarity. We expect to achieve commercial and distribution efficiencies by expanding into related categories that can be marketed through our existing distribution channels or provide us with new distribution channels for our existing products. We plan to only pursue opportunities that we believe meet our acquisition criteria and when we deem it to be financially prudent.
|
|
•
|
Focus on Human Capital.
The success of our business depends on our ability to continue to capitalize on our technical capabilities, unique process know-how, strong customer relationships, and industry knowledge. The technical expertise and history of innovation demonstrated by our employees reflect the specialized and highly skilled nature of our research and development personnel. As such, we intend to focus on attracting, retaining, and developing the best human capital across all levels of our organization, which is key to our ability to successfully operate and grow our business.
|
|
Name
|
|
Title
|
|
Rakesh Sachdev
|
|
Chief Executive Officer
|
|
John P. Connolly
|
|
Chief Financial Officer
|
|
John E. Capps
|
|
Executive Vice President - General Counsel and Secretary
|
|
Benjamin Gliklich
|
|
Executive Vice President - Operations and Strategy
|
|
J. David Tolbert
|
|
Chief Human Resources Officer
|
|
Scot R. Benson
|
|
President - Performance Solutions
|
|
Diego Lopez Casanello
|
|
President - Agricultural Solutions
|
|
•
|
market conditions and volatility;
|
|
•
|
inability or delays in obtaining any legal or regulatory approvals;
|
|
•
|
inability or difficulty in refinancing our Credit Facilities and other material indebtedness, including our Prior Senior Notes;
|
|
•
|
challenges in establishing infrastructure or processes; and
|
|
•
|
the possibility of more attractive strategic options arising in the future.
|
|
•
|
execution of the Proposed Separation requires and will continue to require significant time and attention from management, which may distract management from the operation of our businesses and the execution of other initiatives that may have been beneficial to us;
|
|
•
|
our employees may also be distracted due to uncertainty about their future roles with us and Agricultural Solutions pending the completion of the Proposed Separation;
|
|
•
|
some of our suppliers or customers may delay or defer decisions or may end their relationships with us or our Agricultural Solutions business; and
|
|
•
|
we expect to incur incremental costs and expenses relating to the Proposed Separation, such as legal, accounting, tax and other professional fees.
|
|
•
|
increasing debt levels to fund sizable acquisitions, resulting in additional liabilities, constraints and requirements on our business and financial performance;
|
|
•
|
the acquired businesses failing to provide, or delays in realizing, the benefits originally anticipated by management;
|
|
•
|
potential disruption of our businesses, tax costs or inefficiencies, inconsistencies or deficiencies in standards, controls (including internal control over financial reporting, environmental compliance and health and safety compliance), information technology systems, procedures and policies;
|
|
•
|
difficulties managing tax costs or inefficiencies associated with integrating our operations following completion of acquisitions;
|
|
•
|
difficulties in integrating the operations and systems of the acquired businesses and in realizing operating synergies by identifying and eliminating redundant operations and assets;
|
|
•
|
difficulties in assimilating and retaining key employees, customers, suppliers and other partners of the acquired companies;
|
|
•
|
challenges related to the lack of experience in operating in the geographical or product markets of the acquired business;
|
|
•
|
management’s attention being diverted to the integration of the acquired businesses or acceptance of the acquired technology;
|
|
•
|
rising interest rates on debt needed or dilution resulting from equity issuances to provide cash to fund the purchase price of acquisitions; and
|
|
•
|
unanticipated contract or regulatory issues and the assumption of, and exposure to, unknown or contingent liabilities of the acquired businesses.
|
|
•
|
require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow to fund acquisitions, working capital, capital expenditures, dividends, research and development efforts and other general corporate purposes;
|
|
•
|
increase the amount of our interest expense, because our borrowings include instruments with variable rates of interest, which, if interest rates increase, would result in higher interest expense;
|
|
•
|
increase our vulnerability to general adverse economic and industry conditions;
|
|
•
|
limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;
|
|
•
|
limit our ability to make strategic acquisitions, introduce new technologies or exploit business opportunities;
|
|
•
|
place us at a competitive disadvantage compared to our competitors that have less indebtedness; and
|
|
•
|
limit, among other things, our ability to borrow additional funds.
|
|
•
|
fluctuations in currency values and foreign currency exchange rates;
|
|
•
|
increased credit risk and different financial conditions, which may necessitate longer payment cycles of accounts receivable or result in increased bad debt write-offs (including due to bankruptcy) or additions to reserves;
|
|
•
|
additional withholding taxes or other taxes on foreign income, tariffs, duties, export controls, import restrictions or other restrictions on foreign trade or investment, including currency exchange controls;
|
|
•
|
foreign exchange controls or other currency restrictions and limitation on the movement of funds, including the prohibition of the repatriation of funds into the United States, which may result in adverse tax consequences and tax inefficiencies;
|
|
•
|
export licenses may be difficult to obtain, and the transportation of our products may be delayed or interrupted;
|
|
•
|
general economic and political conditions in the countries in which we operate, including devaluation or fluctuations in the value of currencies, gross domestic product, interest rates, market demand, labor costs and other factors beyond our control;
|
|
•
|
unexpected adverse changes in foreign laws or foreign regulatory requirements, including in laws or regulatory requirements pertaining to employee benefits, the environment and health and safety, such as China's latest environmental crackdown;
|
|
•
|
protectionist policies, which may restrict or impair the manufacturing, sales or import and export of our products;
|
|
•
|
new restrictions on access to markets, such as adverse trade policies or trade barriers;
|
|
•
|
a lack of or inadequate infrastructure;
|
|
•
|
political crises;
|
|
•
|
uncertainties as to the enforceability of contract rights and reduced protection of intellectual property rights in some countries;
|
|
•
|
expropriation of assets or forced relocations of operations;
|
|
•
|
inflation and hyperinflationary economic conditions and adverse economic effects resulting from governmental attempts to control inflation, such as imposition of wage and price controls and higher interest rates;
|
|
•
|
business cultures accepting of various levels of corruption;
|
|
•
|
the requirement to comply with a wide variety of foreign and U.S. laws and regulations that apply to international operations, including, without limitation, economic sanctions regulations, labor laws, import and export regulations, anti-corruption and anti-bribery laws;
|
|
•
|
challenges in maintaining an effective internal control environment with operations in multiple international locations, including language and cultural differences, varying levels of GAAP expertise and internal control over financial reporting in international locations and multiple financial information systems;
|
|
•
|
difficulties managing and administering an internationally dispersed business, as the management of our personnel across many countries can present legal, logistical and managerial challenges; and
|
|
•
|
labor disruptions, civil unrest, significant social, political or economic instability, wars or other armed conflict or acts of terrorism.
|
|
•
|
2,000,000
shares of Series A Preferred Stock which are convertible into shares of our common stock, on a one-for-one basis, at any time at the option of the holder;
|
|
•
|
4,812,742
exchange rights which require us to issue shares of our common stock in exchange for shares of common stock of our subsidiary, PDH, on a one-for-one basis, at any time at the option of the holder;
|
|
•
|
approximately
732,197
options which are exercisable to purchase shares of our common stock, on a one-for-one basis, at any time at the option of the holder, of which
557,197
shares were issued under the 2013 Plan; and
|
|
•
|
approximately
2,943,529
RSUs which were granted to employees under our 2013 Plan. Each RSU represents a contingent right to receive one (1) share of our common stock.
|
|
•
|
quarterly variations in our operating results;
|
|
•
|
changes in the market’s expectations about our operating results;
|
|
•
|
our operating results failing to meet the expectation of management, securities analysts or investors in a particular period;
|
|
•
|
the failure to remediate identified material weaknesses;
|
|
•
|
changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;
|
|
•
|
operating and securities price performance of companies that investors deem comparable to us;
|
|
•
|
news reports and publication of research reports relating to our business or trends in our markets;
|
|
•
|
changes in laws and regulations affecting our businesses;
|
|
•
|
announcements of strategic developments, including the Proposed Separation, or potential future acquisitions or other material events by us or our competitors;
|
|
•
|
sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
|
|
•
|
adverse market reaction to any additional debt we incur in the future;
|
|
•
|
the failure to identify and complete acquisitions in the future or unexpected difficulties or developments related to the integration of recently completed, pending or future acquisitions;
|
|
•
|
actions by institutional stockholders;
|
|
•
|
general economic and political conditions such as recessions and acts of war or terrorism; and
|
|
•
|
the risk factors set forth in this 2017 Annual Report and other matters discussed herein.
|
|
|
|
2017
|
|
2016
|
||||||||||||
|
Period
|
|
High
|
|
Low
|
|
High
|
|
Low
|
||||||||
|
First Quarter
|
|
$
|
13.47
|
|
|
$
|
9.83
|
|
|
$
|
12.22
|
|
|
$
|
5.55
|
|
|
Second Quarter
|
|
14.32
|
|
|
12.11
|
|
|
10.77
|
|
|
7.99
|
|
||||
|
Third Quarter
|
|
14.58
|
|
|
10.92
|
|
|
9.73
|
|
|
8.06
|
|
||||
|
Fourth Quarter
|
|
11.70
|
|
|
9.45
|
|
|
10.40
|
|
|
7.17
|
|
||||
|
($ amounts in millions,
except per share data)
|
|
Year Ended
December 31, 2017 (1) |
|
Year Ended
December 31, 2016 (2) |
|
Year Ended
December 31, 2015 (3) |
|
Year Ended
December 31, 2014 (4) |
|
Period from
Inception (April 23, 2013) through December 31,
2013
(5)
|
|
|
Period from January 1, 2013 through October 31, 2013 (6) |
||||||||||||
|
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
|
(Predecessor)
|
||||||||||||
|
Statement of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
$
|
843.2
|
|
|
$
|
118.2
|
|
|
|
$
|
627.7
|
|
|
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
991.9
|
|
|
396.6
|
|
|
35.7
|
|
|
|
322.8
|
|
||||||
|
Operating profit (loss)
|
|
221.3
|
|
|
253.4
|
|
|
71.6
|
|
|
9.5
|
|
|
(195.6
|
)
|
|
|
91.7
|
|
||||||
|
(Loss) income before income taxes, non-controlling interests and dividends on preferred shares
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(229.3
|
)
|
|
(30.9
|
)
|
|
(201.4
|
)
|
|
|
26.5
|
|
||||||
|
Income tax (expense) benefit
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(75.1
|
)
|
|
6.7
|
|
|
5.8
|
|
|
|
(13.0
|
)
|
||||||
|
Net (loss) income
|
|
(295.6
|
)
|
|
(76.7
|
)
|
|
(304.4
|
)
|
|
(24.2
|
)
|
|
(195.6
|
)
|
|
|
13.5
|
|
||||||
|
Basic loss per share
|
|
(1.04
|
)
|
|
(0.17
|
)
|
|
(1.52
|
)
|
|
(1.94
|
)
|
|
(2.10
|
)
|
|
|
n/a
|
|
||||||
|
Diluted loss per share
|
|
(1.04
|
)
|
|
(0.65
|
)
|
|
(1.52
|
)
|
|
(1.94
|
)
|
|
(2.10
|
)
|
|
|
n/a
|
|
||||||
|
Adjusted EBITDA
(7)
|
|
820.9
|
|
|
769.5
|
|
|
567.7
|
|
|
212.2
|
|
|
27.4
|
|
|
|
n/a
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
|
|
December 31, 2017
(1)
|
|
December 31, 2016
(2)
|
|
December 31, 2015
(3)
|
|
December 31, 2014
(4)
|
|
December 31, 2013
(5)
|
|
|
October 31, 2013
(6)
|
||||||||||||
|
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
(Successor)
|
|
|
(Predecessor)
|
||||||||||||
|
Balance Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Cash and cash equivalents
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
$
|
397.3
|
|
|
$
|
123.0
|
|
|
|
$
|
87.1
|
|
|
Working capital
(8)
|
|
1,248.8
|
|
|
988.5
|
|
|
1,175.2
|
|
|
1,355.8
|
|
|
263.8
|
|
|
|
170.1
|
|
||||||
|
Total assets
|
|
10,252.4
|
|
|
10,054.1
|
|
|
10,190.2
|
|
|
4,547.3
|
|
|
2,258.5
|
|
|
|
1,172.0
|
|
||||||
|
Total debt
|
|
5,479.5
|
|
|
5,239.0
|
|
|
5,228.3
|
|
|
1,405.6
|
|
|
750.6
|
|
|
|
1,107.4
|
|
||||||
|
Total equity (deficit)
|
|
2,860.0
|
|
|
2,889.8
|
|
|
2,273.3
|
|
|
2,552.6
|
|
|
1,115.1
|
|
|
|
(200.0
|
)
|
||||||
|
(1)
|
The results presented include the following significant items affecting comparability for the year ended December 31, 2017:
|
|
•
|
Goodwill impairment charge of
$160 million
related to our Agro Business reporting unit in our Agricultural Solutions segment;
|
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$103 million
;
|
|
•
|
Debt refinancing charges of
$83.2 million
;
|
|
•
|
Restructuring costs of
$30.8 million
, primarily related to severance;
|
|
•
|
Costs related to our Proposed Separation of
$12.1 million
;
|
|
•
|
Pension plan settlement and curtailment costs of
$10.5 million
;
|
|
•
|
Net interest expense of
$342 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, impacted by the repricing of our term debt; and
|
|
•
|
Effective tax rate changed from
(59.5)%
for 2016 to
(2.3)%
for 2017 primarily due to the increased level of goodwill impairment in 2017 as compared to 2016 for which there was no corresponding tax benefit, the benefit for the provisional estimate of the TCJA, the 2016 settlement gain of the Series B Convertible Preferred Stock which was treated as a non-taxable purchase price adjustment, and favorable reductions in foreign tax rates for changes in tax law.
|
|
(2)
|
In addition to the impact of the 2016 and 2015 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2016:
|
|
•
|
Goodwill impairment charge of
$46.6 million
related to Performance Solutions' Offshore Solutions reporting unit;
|
|
•
|
Amortization of inventory step-up of
$11.7 million
charged to cost of sales;
|
|
•
|
Acquisition and integration related costs of
$33.4 million
, primarily comprised of professional fees;
|
|
•
|
Restructuring costs of
$31.1 million
, primarily related to severance;
|
|
•
|
Net interest expense of
$376 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund the acquisitions;
|
|
•
|
Gains relating to the amendment of the Series B Convertible Preferred Stock and the related execution of a settlement agreement totaling
$32.9 million
and
$103 million
, respectively;
|
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$33.9 million
;
|
|
•
|
Debt refinancing charges of
$19.7 million
; and
|
|
•
|
Income tax expense which included a
$34.3 million
benefit related to the settlement of Series B Convertible Preferred Stock, a
$24.5 million
benefit related to the impact of transaction costs, and a
$24.1 million
benefit related to a net change in tax reserves, partially offset by
$68.4 million
of expense related to a change in valuation allowances and
$26.8 million
of expense related to an increase in the provision for tax on undistributed foreign earnings.
|
|
(3)
|
In addition to the impact of the 2015 and 2014 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2015:
|
|
•
|
Amortization of inventory step-up of
$76.5 million
charged to cost of sales;
|
|
•
|
Acquisition and integration related costs of
$122 million
, primarily comprised of professional fees;
|
|
•
|
Restructuring costs of
$25.3 million
, primarily related to severance, professional and consulting fees;
|
|
•
|
Net interest expense of
$214 million
, primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund the acquisitions;
|
|
•
|
Fair value loss on foreign exchange forward contract related to the Alent Acquisition of
$73.7 million
charged to other expense;
|
|
•
|
Foreign exchange loss on foreign denominated external and internal long-term debt of
$46.4 million
; and
|
|
•
|
Income tax expense which included
$72.6 million
of expense related to a change in valuation allowances,
$40.5 million
of expense related to non-deductible transaction costs, and
$27.5 million
of expense related to a net change in tax reserves.
|
|
(4)
|
In addition to the impact of the 2014 and 2013 acquisitions and related valuation of intangible assets, the results presented include the following significant items affecting comparability for the year ended December 31, 2014:
|
|
•
|
Amortization of inventory step-up of
$35.5 million
charged to cost of sales;
|
|
•
|
Acquisition and integration related costs of
$47.8 million
, primarily comprised of professional fees;
|
|
•
|
Net interest expense of
$37.9 million
' primarily related to interest charges resulting from incremental debt facilities, including term loans, bonds and revolving credit borrowings, used to fund acquisitions; and
|
|
•
|
Non-cash mark-to-market charge related to the contingent consideration in connection with the MacDermid acquisition of
$29.1 million
.
|
|
(5)
|
The results presented include the following significant items affecting comparability in the Successor 2013 Period:
|
|
•
|
Non-cash charge related to the preferred share dividend rights of the Founders Entities of
$172 million
;
|
|
•
|
Amortization of inventory step-up of
$23.9 million
charged to cost of sales; and
|
|
•
|
Transaction related costs, primarily comprised of professional fees, of
$15.2 million
.
|
|
(6)
|
The results presented include the following significant items affecting comparability in the Predecessor 2013 Period:
|
|
•
|
Transaction related costs, primarily for professional fees, and fees paid to Predecessor stockholders resulting from management fees payable in conjunction with consummation of the MacDermid Acquisition of
$16.9 million
; and
|
|
•
|
Deemed compensation expense related to pre-acquisition share awards of approximately
$9.3 million
.
|
|
(7)
|
Adjusted EBITDA is a non-GAAP financial measure and as such, should not be considered in isolation from, as a substitute for, or superior to performance measures calculated in accordance with GAAP. For a definition of Adjusted EBITDA and additional information on why we present this measure, its limitations and a reconciliation to the most comparable applicable GAAP measure, see "
Non-GAAP Financial Measures"
in the Management's Discussion and Analysis of Financial Condition and Results of Operations section included in Part II, Item 7, and Note 23,
Segment Information
, to the Consolidated Financial Statements, all included in this 2017 Annual Report.
|
|
(8)
|
Working capital is defined as current assets less current liabilities.
|
|
•
|
In April 2017
, we completed the repricing of
$1.93 billion
of existing term loans through Amendment No. 7 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of
$1.23 billion
and term loans denominated in euros in an aggregate principal amount of
€650 million
. The amendment effectively reduced interest rates by
100
basis points across both the U.S. dollar and euro tranches. In addition, the EURIBOR floor was reduced from
1.00%
to
0.75%
on the new euro denominated term loans. At the close of this refinancing, the reduced interest rates were expected to generate annual cash savings of approximately
$20.0 million
, based on foreign exchange rates then in effect.
|
|
•
|
In June 2017
, MacDermid Printing and E.I. du Pont de Nemours and Company, now known as DowDuPont Inc. ("DuPont"), settled all outstanding litigation between them, as well as MacDermid Printing's lawsuit against Cortron. In connection with this settlement, DuPont made a payment of
$20.0 million
to MacDermid Printing, and we recorded a net settlement gain of
$10.8 million
.
|
|
•
|
In October 2017
, we completed the repricing of
$1.40 billion
of existing term loans through Amendment No. 8 to the Second Amended and Restated Credit Agreement which, among other things, provided for the prepayment in full of previously existing term loans denominated in U.S. dollars and in euros with the aggregate proceeds of newly created term loans denominated in U.S. dollars in an aggregate principal amount of
$680 million
and term loans denominated in euros in an aggregate principal amount of
€630 million
. This amendment effectively reduced interest rates by
100
basis points across both the U.S. dollar and euro tranches from a combination of reduced spread and reduced EURIBOR floor from
1.00%
to
0.75%
on the new euro denominated term loans. At the close of this refinancing, the reduced interest rates were expected to generate annual cash savings of approximately
$14.0 million
, based on foreign exchange rates then in effect.
|
|
•
|
In November 2017
, we completed a private offering of
$550 million
aggregate principal amount of
5.875%
USD Notes due 2025. The proceeds from this offering were used to pay the consideration of the below-mentioned cash tender offer and consent solicitation for, as well as redemption of, any and all of our then outstanding 10.375% USD Notes due 2021, plus accrued and unpaid interest on the 10.375% USD Notes due 2021, along with fees and expenses.
|
|
•
|
In December 2017
, we completed a tack-on private offering of
$250 million
aggregate principal amount of additional 5.875% USD Notes due 2025. The additional notes have the same terms as, and are fungible and form a single series with, the 5.875% USD Notes due 2025 issued in November 2017. The proceeds from this offering were used to repay a portion of our existing terms loans under our Amended and Restated Credit Agreement. The 5.875% USD Notes Indenture provides that in connection with the satisfaction of certain financial covenants and other conditions, all of the then direct and indirect subsidiaries constituting our Agricultural Solutions business may be designated as unrestricted subsidiaries and, as applicable, released from their guarantees of the 5.875% USD Notes due 2025.
|
|
•
|
In December 2017
, we completed the cash tender offer and consent solicitation for, as well as the redemption of, any and all of our then outstanding 10.375% USD Notes due 2021. The tender offer and consent solicitation, as well as the redemption, were financed with the proceeds of the November offering of 5.875% USD Notes due 2025 described above.
|
|
•
|
Valuation Techniques
- we use a discounted cash flow analysis, which requires assumptions about short and long-term net cash flows, growth rates, as well as discount rates. Additionally, we consider guideline company and guideline transaction information, where available, to aid in the valuation of the reporting units.
|
|
•
|
Growth Assumptions
- Multi-year financial forecasts are developed for each reporting unit by considering several key business drivers such as new business initiatives, client service and retention standards, market share changes, historical performance, and industry and economic trends, among other considerations. We typically forecast revenue and the resulting cash flows for periods of five to seven years and include an estimated terminal growth rate at the end of the forecasted period.
|
|
•
|
Discount Rate Assumptions
- Discount rates are estimated based on the WACC, which combines the required return on equity and considers the risk-free interest rate, market risk premium, small stock risk premium and a company specific risk premium, with the cost of debt, based on BBB-rated corporate bonds, adjusted using an income tax factor.
|
|
•
|
Estimated Fair Value and Sensitivitie
s - The estimated fair value of each reporting unit is derived from the valuation techniques described above. The estimated fair value of each reporting unit is analyzed in relation to numerous market and historical factors, including current economic and market conditions, company-specific growth opportunities, and guideline company information.
|
|
|
|
|
|
% Change - 2017 vs 2016
|
|
|
|
% Change - 2016 vs 2015
|
||||||||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||||
|
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
5%
|
|
4%
|
|
4%
|
|
$
|
2,542.3
|
|
|
41%
|
|
43%
|
|
2%
|
|
Cost of sales
|
|
2,186.9
|
|
|
2,078.2
|
|
|
5%
|
|
4%
|
|
|
|
1,550.4
|
|
|
34%
|
|
36%
|
|
|
|||
|
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
5%
|
|
5%
|
|
|
|
991.9
|
|
|
52%
|
|
55%
|
|
|
|||
|
Selling, technical, general and administrative
|
|
1,109.3
|
|
|
1,123.3
|
|
|
(1)%
|
|
(2)%
|
|
|
|
857.5
|
|
|
31%
|
|
33%
|
|
|
|||
|
Research and development
|
|
98.4
|
|
|
84.4
|
|
|
17%
|
|
15%
|
|
|
|
62.8
|
|
|
34%
|
|
35%
|
|
|
|||
|
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
(nm)
|
|
(nm)
|
|
|
|
—
|
|
|
(nm)
|
|
(nm)
|
|
|
|||
|
Operating profit
|
|
221.3
|
|
|
253.4
|
|
|
(13)%
|
|
(9)%
|
|
|
|
71.6
|
|
|
(nm)
|
|
(nm)
|
|
|
|||
|
Interest expense, net
|
|
(341.6
|
)
|
|
(375.7
|
)
|
|
(9)%
|
|
|
|
|
|
(213.9
|
)
|
|
76%
|
|
|
|
|
|||
|
Other (expense) income, net
|
|
(168.7
|
)
|
|
74.2
|
|
|
(nm)
|
|
|
|
|
|
(87.0
|
)
|
|
(nm)
|
|
|
|
|
|||
|
Loss before income taxes and non-controlling interest
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(nm)
|
|
|
|
|
|
(229.3
|
)
|
|
(79)%
|
|
|
|
|
|||
|
Income tax expense
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(77)%
|
|
|
|
|
|
(75.1
|
)
|
|
(62)%
|
|
|
|
|
|||
|
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
(nm)
|
|
|
|
|
|
$
|
(304.4
|
)
|
|
(75)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Adjusted EBITDA
(1)
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
7%
|
|
7%
|
|
|
|
$
|
567.7
|
|
|
36%
|
|
38%
|
|
|
|
|
Year ended December 31, 2017
|
||||||||
|
|
Reported Net Sales Growth
|
|
Impact of Currency
|
|
Metals
|
|
Acquisitions/Disposition
|
|
Organic Sales Growth
|
|
Performance Solutions
|
6%
|
|
—%
|
|
(1)%
|
|
—%
|
|
4%
|
|
Agricultural Solutions
|
4%
|
|
(2)%
|
|
—%
|
|
—%
|
|
3%
|
|
Total
|
5%
|
|
(1)%
|
|
(1)%
|
|
—%
|
|
4%
|
|
|
Year ended December 31, 2016
|
||||||||
|
|
Reported Net Sales Growth
|
|
Impact of Currency
|
|
Metals
|
|
Acquisitions/Disposition
|
|
Organic Sales Growth
|
|
Performance Solutions
|
121%
|
|
2%
|
|
(2)%
|
|
(120)%
|
|
1%
|
|
Agricultural Solutions
|
4%
|
|
2%
|
|
—%
|
|
(3)%
|
|
3%
|
|
Total
|
41%
|
|
2%
|
|
—%
|
|
(40)%
|
|
2%
|
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Performance Solutions
|
$
|
1,878.6
|
|
|
$
|
1,770.1
|
|
|
6%
|
|
6%
|
|
4%
|
|
Agricultural Solutions
|
1,897.3
|
|
|
1,815.8
|
|
|
4%
|
|
3%
|
|
3%
|
||
|
Total
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
5%
|
|
4%
|
|
4%
|
|
|
Year ended December 31,
|
|
Change
|
||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
|
Gross profit
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
813.8
|
|
|
$
|
776.8
|
|
|
5%
|
|
5%
|
|
Agricultural Solutions
|
775.2
|
|
|
730.9
|
|
|
6%
|
|
5%
|
||
|
Total
|
$
|
1,589.0
|
|
|
$
|
1,507.7
|
|
|
5%
|
|
5%
|
|
|
|
|
|
|
|
|
|
||||
|
Gross margin
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
43.3%
|
|
43.9%
|
|
(57) bps
|
|
(49) bps
|
||||
|
Agricultural Solutions
|
40.9%
|
|
40.3%
|
|
61 bps
|
|
95 bps
|
||||
|
Total
|
42.1%
|
|
42.0%
|
|
4 bps
|
|
24 bps
|
||||
|
|
Year ended December 31,
|
|
Change
|
||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
|
STG&A
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
504.1
|
|
|
$
|
504.3
|
|
|
—%
|
|
—%
|
|
Agricultural Solutions
|
525.3
|
|
|
518.1
|
|
|
1%
|
|
(1)%
|
||
|
Corporate
|
79.9
|
|
|
100.9
|
|
|
(21)%
|
|
(21)%
|
||
|
Total
|
$
|
1,109.3
|
|
|
$
|
1,123.3
|
|
|
(1)%
|
|
(2)%
|
|
|
|
|
|
|
|
|
|
||||
|
STG&A as % of net sales
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
26.8%
|
|
28.5%
|
|
(165) bps
|
|
(169) bps
|
||||
|
Agricultural Solutions
|
27.7%
|
|
28.5%
|
|
(85) bps
|
|
(103) bps
|
||||
|
Total
|
29.4%
|
|
31.3%
|
|
(195) bps
|
|
(204) bps
|
||||
|
|
Year ended December 31,
|
|
Change
|
||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
|
R&D
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
46.4
|
|
|
$
|
45.0
|
|
|
3%
|
|
4%
|
|
Agricultural Solutions
|
52.0
|
|
|
39.4
|
|
|
32%
|
|
28%
|
||
|
Total
|
$
|
98.4
|
|
|
$
|
84.4
|
|
|
17%
|
|
15%
|
|
|
|
|
|
|
|
|
|
||||
|
R&D as % of net sales
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
2.5%
|
|
2.5%
|
|
(7) bps
|
|
(5) bps
|
||||
|
Agricultural Solutions
|
2.7%
|
|
2.2%
|
|
57 bps
|
|
53 bps
|
||||
|
Total
|
2.6%
|
|
2.4%
|
|
25 bps
|
|
24 bps
|
||||
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
||||
|
Goodwill impairment
|
|
|
|
||||
|
Performance Solutions
|
$
|
—
|
|
|
$
|
46.6
|
|
|
Agricultural Solutions
|
160.0
|
|
|
—
|
|
||
|
Total
|
$
|
160.0
|
|
|
$
|
46.6
|
|
|
|
Year ended December 31,
|
|
Change
|
||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
|
Operating profit
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
263.2
|
|
|
$
|
180.9
|
|
|
45%
|
|
46%
|
|
Agricultural Solutions
|
38.0
|
|
|
173.4
|
|
|
(78)%
|
|
(74)%
|
||
|
Corporate
|
(79.9
|
)
|
|
(100.9
|
)
|
|
(21)%
|
|
(21)%
|
||
|
Total
|
$
|
221.3
|
|
|
$
|
253.4
|
|
|
(13)%
|
|
(9)%
|
|
|
|
|
|
|
|
|
|
||||
|
Operating Margin
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
14.0%
|
|
10.2%
|
|
379 bps
|
|
389 bps
|
||||
|
Agricultural Solutions
|
2.0%
|
|
9.5%
|
|
(755) bps
|
|
(711) bps
|
||||
|
Total
|
5.9%
|
|
7.1%
|
|
(121) bps
|
|
(94) bps
|
||||
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
||||
|
Interest expense, net
|
$
|
(341.6
|
)
|
|
$
|
(375.7
|
)
|
|
Foreign exchange loss
|
(107.5
|
)
|
|
(14.1
|
)
|
||
|
Other (expense) income, net
|
(61.2
|
)
|
|
88.3
|
|
||
|
Total
|
$
|
(510.3
|
)
|
|
$
|
(301.5
|
)
|
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
||||
|
Income tax expense
|
$
|
(6.6
|
)
|
|
$
|
(28.6
|
)
|
|
Effective tax rate
|
(2.3
|
)%
|
|
(59.5
|
)%
|
||
|
|
Year Ended December 31,
|
|
Change
|
||||||||
|
($ amounts in millions)
|
2017
|
|
2016
|
|
Reported
|
|
Constant Currency
|
||||
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
||
|
Performance Solutions
|
$
|
432.7
|
|
|
$
|
401.3
|
|
|
8%
|
|
8%
|
|
Agricultural Solutions
|
388.2
|
|
|
368.2
|
|
|
5%
|
|
6%
|
||
|
Total
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
7%
|
|
7%
|
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Performance Solutions
|
$
|
1,770.1
|
|
|
$
|
800.8
|
|
|
121%
|
|
123%
|
|
1%
|
|
Agricultural Solutions
|
1,815.8
|
|
|
1,741.5
|
|
|
4%
|
|
6%
|
|
3%
|
||
|
Total
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
41%
|
|
43%
|
|
2%
|
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Gross profit
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
776.8
|
|
|
$
|
387.9
|
|
|
100%
|
|
103%
|
|
1%
|
|
Agricultural Solutions
|
730.9
|
|
|
604.0
|
|
|
21%
|
|
23%
|
|
19%
|
||
|
Total
|
$
|
1,507.7
|
|
|
$
|
991.9
|
|
|
52%
|
|
55%
|
|
12%
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Gross margin
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
43.9%
|
|
48.4%
|
|
(455) bps
|
|
(441) bps
|
|
(91) bps
|
||||
|
Agricultural Solutions
|
40.3%
|
|
34.7%
|
|
557 bps
|
|
554 bps
|
|
554 bps
|
||||
|
Total
|
42.0%
|
|
39.0%
|
|
303 bps
|
|
309 bps
|
|
381 bps
|
||||
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
STG&A
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
504.3
|
|
|
$
|
242.6
|
|
|
108%
|
|
110%
|
|
13%
|
|
Agricultural Solutions
|
518.1
|
|
|
488.5
|
|
|
6%
|
|
9%
|
|
3%
|
||
|
Corporate
|
100.9
|
|
|
126.4
|
|
|
(20)%
|
|
(20)%
|
|
(20)%
|
||
|
Total
|
$
|
1,123.3
|
|
|
$
|
857.5
|
|
|
31%
|
|
33%
|
|
2%
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
STG&A as % of net sales
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
28.5%
|
|
30.3%
|
|
(180) bps
|
|
(177) bps
|
|
286 bps
|
||||
|
Agricultural Solutions
|
28.5%
|
|
28.1%
|
|
48 bps
|
|
67 bps
|
|
67 bps
|
||||
|
Total
|
31.3%
|
|
33.7%
|
|
(240) bps
|
|
(233) bps
|
|
(30) bps
|
||||
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
R&D
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
45.0
|
|
|
$
|
25.4
|
|
|
77%
|
|
78%
|
|
(12)%
|
|
Agricultural Solutions
|
39.4
|
|
|
37.4
|
|
|
5%
|
|
5%
|
|
(4)%
|
||
|
Total
|
$
|
84.4
|
|
|
$
|
62.8
|
|
|
34%
|
|
35%
|
|
(7)%
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
R&D as % of net sales
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
2.5%
|
|
3.2%
|
|
(63) bps
|
|
(64) bps
|
|
(47) bps
|
||||
|
Agricultural Solutions
|
2.2%
|
|
2.1%
|
|
2 bps
|
|
(2) bps
|
|
(2) bps
|
||||
|
Total
|
2.4%
|
|
2.5%
|
|
(12) bps
|
|
(15) bps
|
|
(23) bps
|
||||
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
||||
|
Goodwill impairment
|
$
|
46.6
|
|
|
$
|
—
|
|
|
|
Year ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Operating profit
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
180.9
|
|
|
$
|
119.9
|
|
|
51%
|
|
55%
|
|
(50)%
|
|
Agricultural Solutions
|
173.4
|
|
|
78.6
|
|
|
120%
|
|
121%
|
|
134%
|
||
|
Corporate
|
(100.9
|
)
|
|
(126.9
|
)
|
|
(20)%
|
|
(20)%
|
|
(20)%
|
||
|
Total
|
$
|
253.4
|
|
|
$
|
71.6
|
|
|
253%
|
|
260%
|
|
77%
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Operating Margin
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
10.2%
|
|
15.0%
|
|
(475) bps
|
|
(460) bps
|
|
(967) bps
|
||||
|
Agricultural Solutions
|
9.5%
|
|
4.5%
|
|
504 bps
|
|
486 bps
|
|
486 bps
|
||||
|
Total
|
7.1%
|
|
2.8%
|
|
425 bps
|
|
427 bps
|
|
245 bps
|
||||
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
||||
|
Interest expense, net
|
$
|
(375.7
|
)
|
|
$
|
(213.9
|
)
|
|
Foreign exchange loss
|
(14.1
|
)
|
|
(43.4
|
)
|
||
|
Other income (expense), net
|
88.3
|
|
|
(43.6
|
)
|
||
|
Total
|
$
|
(301.5
|
)
|
|
$
|
(300.9
|
)
|
|
|
Year Ended December 31,
|
||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
||||
|
Income tax expense
|
$
|
(28.6
|
)
|
|
$
|
(75.1
|
)
|
|
Effective tax rate
|
(59.5
|
)%
|
|
(32.8
|
)%
|
||
|
|
Year Ended December 31,
|
|
Change
|
||||||||||
|
($ amounts in millions)
|
2016
|
|
2015
|
|
Reported
|
|
Constant Currency
|
|
Organic
|
||||
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
||||
|
Performance Solutions
|
$
|
401.3
|
|
|
$
|
224.3
|
|
|
79%
|
|
86%
|
|
9%
|
|
Agricultural Solutions
|
368.2
|
|
|
343.4
|
|
|
7%
|
|
7%
|
|
6%
|
||
|
Total
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
36%
|
|
38%
|
|
8%
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Cash and cash equivalents, beginning of the period
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
$
|
397.3
|
|
|
Cash provided by operating activities
|
|
182.1
|
|
|
184.8
|
|
|
320.9
|
|
|||
|
Cash used in investing activities
|
|
(92.6
|
)
|
|
(74.7
|
)
|
|
(4,256.5
|
)
|
|||
|
Cash (used in) provided by financing activities
|
|
(67.4
|
)
|
|
(102.2
|
)
|
|
4,001.2
|
|
|||
|
Exchange rate impact on cash and cash equivalents
|
|
33.1
|
|
|
(17.5
|
)
|
|
(30.7
|
)
|
|||
|
Cash and cash equivalents, end of the period
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
•
|
$2.28 billion
of Senior Notes;
|
|
•
|
$3.15 billion
of term debt arrangements outstanding under our First Lien Credit Facility; and
|
|
•
|
$28.5 million
of borrowings under local and revolving lines of credit.
|
|
|
|
|
|
Payment Due by Period
|
||||||||||||||||||||||||||
|
($ amounts in millions)
|
|
|
|
2018
|
|
2019
|
|
2020
|
|
2021
|
|
2022
|
|
Thereafter
|
|
Total
|
||||||||||||||
|
Long-term debt
|
|
(1)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,330.8
|
|
|
$
|
1,854.4
|
|
|
$
|
1,100.0
|
|
|
$
|
1,219.9
|
|
|
$
|
5,505.1
|
|
|
Operating leases
|
|
(2)
|
|
33.0
|
|
|
25.0
|
|
|
19.6
|
|
|
13.9
|
|
|
12.1
|
|
|
28.9
|
|
|
132.5
|
|
|||||||
|
Interest payments (net of interest rate swap effects)
|
|
(3)
|
|
276.7
|
|
|
276.7
|
|
|
247.6
|
|
|
212.2
|
|
|
111.0
|
|
|
155.1
|
|
|
1,279.3
|
|
|||||||
|
Long-term contingent consideration
|
|
(4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
100.0
|
|
|
—
|
|
|
—
|
|
|
100.0
|
|
|||||||
|
Principal payments on capital leases
|
|
|
|
0.7
|
|
|
0.6
|
|
|
0.5
|
|
|
0.5
|
|
|
0.4
|
|
|
1.6
|
|
|
4.3
|
|
|||||||
|
Purchase obligations
|
|
(5)
|
|
72.2
|
|
|
1.1
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
73.5
|
|
|||||||
|
Other long term obligations
|
|
(6)
|
|
8.9
|
|
|
4.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
13.3
|
|
|
26.4
|
|
|||||||
|
Total cash contractual obligations
|
|
|
|
$
|
391.5
|
|
|
$
|
307.6
|
|
|
$
|
1,598.7
|
|
|
$
|
2,181.0
|
|
|
$
|
1,223.5
|
|
|
$
|
1,418.8
|
|
|
$
|
7,121.1
|
|
|
(1)
|
Reflects the principal payments on long-term debt. In the event the Company is able to prepay, redeem or otherwise retire and/or refinance in full its
$1.1 billion
,
6.50%
USD Notes due 2022, as permitted under the Amended and Restated Credit Agreement, on or prior to November 2, 2021, the maturity date of approximately
$1.85 billion
of first lien debt will be extended to June 7, 2023 from November 2, 2021, as currently presented in the table above.
|
|
(2)
|
Reflects periodic payments made in accordance with operating lease agreements.
|
|
(3)
|
Amounts are based on currently applicable interest rates in the case of variable interest rate debt and associated floating and floor legs of the interest rate swaps.
|
|
(4)
|
Reflects the maximum payout in 2021 of 100% of long-term contingent consideration related to the MacDermid Acquisition. At
December 31, 2017
, the long-term contingent consideration related to the MacDermid Acquisition was valued at
$79.2 million
. See Note 13,
Financial Instruments
, to the Consolidated Financial Statements included in this 2017 Annual Report for additional information.
|
|
(5)
|
Purchase obligations represent amounts committed under legally enforceable supply agreements and non-cancelable purchase contracts. We do not include purchase obligations that can be canceled with a nominal fee.
|
|
(6)
|
Other long-term obligations consist of asset retirement obligations, or AROs.
|
|
•
|
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;
|
|
•
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of our financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
|
•
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.
|
|
•
|
implementing a global consolidation and planning system;
|
|
•
|
implementing control processes relating to newly-acquired businesses and non-routine transactions;
|
|
•
|
implementing enhanced monitoring controls relating to the financial reporting and performance of our newly-acquired businesses; and
|
|
•
|
enhancing our financial planning and analysis function within our businesses and at the corporate level.
|
|
•
|
improving the overall tax provision process; and
|
|
•
|
enhancing our income tax controls to include specific activities to assess the accounting for significant complex transactions and other tax related judgments.
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
|
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
|
2.1
|
|
Settlement Agreement and Release, dated September 9, 2016
, among Platform and MacDermid Agricultural Solutions, Inc. and Permira Advisers LLC, Nalozo S.à.r.l., and Nalozo L.P.
|
|
8-K
|
|
001-36272
|
|
2.1
|
|
9/12/2016
|
|
|
|
3.1 (a)
|
|
|
S-4 POS
|
|
333-192778
|
|
3.1
|
|
1/24/2014
|
|
|
|
|
3.1 (b)
|
|
|
8-K
|
|
001-36272
|
|
3.1
|
|
6/13/2014
|
|
|
|
|
3.2
|
|
|
10-K
|
|
001-36272
|
|
3.2
|
|
3/31/2014
|
|
|
|
|
4.1
|
|
|
S-4/A
|
|
333-192778
|
|
4.1
|
|
1/2/2014
|
|
|
|
|
4.2
|
|
Indenture, dated as of February 2, 2015
, among Escrow Issuer, the Trustee and the EUR Agent
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
2/3/2015
|
|
|
|
4.3
|
|
Supplemental Indenture, dated as of February 13, 2015
, among Platform, the Initial Guarantors, the Trustee and the EUR Agent
|
|
8-K
|
|
001-36272
|
|
4.2
|
|
2/17/2015
|
|
|
|
4.4
|
|
Second Supplemental Indenture, dated as of May 20, 2015
, among Platform, the Subsequent Guarantors, the other Guarantors, the Trustee, and the EUR Agent
|
|
10-K
|
|
001-36272
|
|
4.4
|
|
3/11/2016
|
|
|
|
4.5
|
|
Third Supplemental Indenture, dated as of January 26, 2016
, among Platform, the Subsequent Guarantors, the Trustee, and the EUR Agent
|
|
10-K
|
|
001-36272
|
|
4.5
|
|
3/11/2016
|
|
|
|
4.6
|
|
Fourth Supplemental Indenture, dated as of April 13, 2016
, among Platform, the Subsequent Guarantors, the Trustee and the EUR Agent
|
|
10-Q
|
|
001-36272
|
|
4.1
|
|
8/9/2016
|
|
|
|
4.7
|
|
|
8-K
|
|
001-36272
|
|
A-1 to 4.1
|
|
2/3/2015
|
|
|
|
|
4.8
|
|
|
8-K
|
|
001-36272
|
|
A-2 to 4.1
|
|
2/3/2015
|
|
|
|
|
4.9
|
|
Indenture, dated as of November 10, 2015
, among PSPC Escrow II Corp. and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
11/12/2015
|
|
|
|
4.10
|
|
Supplemental Indenture, dated as of December 1, 2015
, among Platform, the Initial Guarantors and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.2
|
|
12/4/2015
|
|
|
|
4.11
|
|
Second Supplemental Indenture, dated as of January 26, 2016
, among Platform, the Subsequent Guarantors, and the Trustee
|
|
10-K
|
|
001-36272
|
|
4.10
|
|
3/11/2016
|
|
|
|
4.12
|
|
Third Supplemental Indenture, dated as of April 13, 2016
, among Platform, the Subsequent Guarantors and the Trustee
|
|
10-Q
|
|
001-36272
|
|
4.2
|
|
8/9/2016
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
|
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
|
4.13
|
|
Form of 10.375% senior notes due 2021
(Exhibit A)
|
|
8-K
|
|
001-36272
|
|
A to 4.1
|
|
11/12/2015
|
|
|
|
4.14
|
|
Indenture, dated as of November 24, 2017
, among Platform, the guarantors named therein and the Trustee
|
|
8-K
|
|
001-36272
|
|
4.1
|
|
11/27/2017
|
|
|
|
4.15
|
|
Form of 5.875% senior notes due 2025
(Exhibit A)
|
|
8-K
|
|
001-36272
|
|
A to 4.01
|
|
11/27/2017
|
|
|
|
†10.1
|
|
Employment Agreement, dated as of December 15, 2015
, between Platform and Rakesh Sachdev (effective January 5, 2016)
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
12/16/2015
|
|
|
|
†10.2
|
|
Time and Performance-Based Restricted Stock Unit Award Agreement
by and between Platform and Rakesh Sachdev (effective January 5, 2016)
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
12/16/2015
|
|
|
|
†10.3
|
|
|
10-Q
|
|
001-36272
|
|
10.6
|
|
5/9/2017
|
|
|
|
|
10.4
|
|
MacDermid, Incorporated Employees’ Pension Plan
(as amended and restated generally effective January 1, 2009)
|
|
S-4
|
|
333-192778
|
|
10.6
|
|
12/11/2013
|
|
|
|
10.5
|
|
Second Amendment to MacDermid, Incorporated Employees’ Pension Plan, 2009 Restatement
(effective as of January 1, 2009)
|
|
S-4/A
|
|
333-192778
|
|
10.8
|
|
1/2/2014
|
|
|
|
10.6
|
|
Third Amendment to Amended and Restated MacDermid, Incorporated Employees’ Pension Plan
(effective as of January 1, 2009)
|
|
S-4/A
|
|
333-192778
|
|
10.21
|
|
1/2/2014
|
|
|
|
10.7
|
|
MacDermid, Incorporated Supplemental Executive Retirement Plan
, effective April 1, 1994, as amended on February 25, 2005, and as further amended on July 11, 2013
|
|
S-4/A
|
|
333-192778
|
|
10.7
|
|
1/2/2014
|
|
|
|
10.8
|
|
Amendment No. 1, dated as of December 13, 2013, to MacDermid, Incorporated Supplemental Executive Retirement Plan
(as Previously Amended and Restated)
|
|
S-4/A
|
|
333-192778
|
|
10.9
|
|
1/2/2014
|
|
|
|
†10.9
|
|
Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, effective as of January 1, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(a)
|
|
6/29/2015
|
|
|
|
†10.10
|
|
Amendment No. 2 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of September 8, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(b)
|
|
6/29/2015
|
|
|
|
†10.11
|
|
Amendment No. 3 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of November 17, 2014
|
|
S-8
|
|
333-205340
|
|
4.2(c)
|
|
6/29/2015
|
|
|
|
†10.12
|
|
Amendment No. 4 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated as of February 10, 2015
|
|
S-8
|
|
333-205340
|
|
4.2(d)
|
|
6/29/2015
|
|
|
|
†10.13
|
|
Amendment No.5 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated October 31, 2105
|
|
10-Q
|
|
001-36272
|
|
10.1
|
|
8/9/2016
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
|
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
|
†10.14
|
|
Amendment No.6 to Platform Specialty Products Corporation Employee Savings and 401(k) Plan
, dated April 21, 2016
|
|
10-Q
|
|
001-36272
|
|
10.2
|
|
8/9/2016
|
|
|
|
†10.15
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
(Appendix A) (effective as of November 1, 2013)
|
|
DEF14A
|
|
001-36272
|
|
Appendix A
|
|
4/25/2014
|
|
|
|
†10.16
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan
(Appendix B) (effective as of March 6, 2014)
|
|
DEF14A
|
|
001-36272
|
|
Appendix B
|
|
4/25/2014
|
|
|
|
†10.17
|
|
Form of Restricted Stock Unit Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
S-4
|
|
333-192778
|
|
10.11
|
|
1/2/2014
|
|
|
|
†10.18
|
|
Form of Performance-Based Restricted Stock Unit Award Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
3/25/2016
|
|
|
|
†10.19
|
|
Form of Non-Qualified Stock Option Agreemen
t – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
3/25/2016
|
|
|
|
10.20
|
|
Form of Long Term Cash Bonus Award Agreement
– Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan
|
|
10-K
|
|
001-36272
|
|
10.24
|
|
3/11/2016
|
|
|
|
†10.21
|
|
|
S-4/A
|
|
333-192778
|
|
10.12
|
|
1/2/2014
|
|
|
|
|
†10.22
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
10.23
|
|
Amended and Restated Credit Agreement, dated as of October 31, 2013
, among, inter alia, Platform Acquisition Holding Limited, MacDermid Holdings, LLC, Matrix Acquisition Corp., MacDermid, Incorporated (as successor to Matrix Acquisition Corp., the borrower), the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Credit Suisse AG, as administrative agent and as collateral agent
|
|
S-4/A
|
|
333-192778
|
|
10.13
|
|
1/2/2014
|
|
|
|
10.24
|
|
Second Amended and Restated Credit Agreement, dated as of August 6, 2014
, among, inter alia, the Company, MacDermid Holdings, LLC, MacDermid, Incorporated, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
8/8/2014
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
|
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
|
10.25
|
|
Amendment No. 2, dated as of August 6, 2014
, among, inter alia, the Company, MacDermid Holdings, LLC, MacDermid, Incorporated, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.2
|
|
8/8/2014
|
|
|
|
10.26
|
|
Incremental Amendment No. 1, dated as of October 1, 2014
, among the Company, MacDermid, Incorporated, MacDermid Holdings, LLC, certain subsidiaries of MacDermid Holdings, LLC and Platform party thereto, Barclays Bank PLC, as collateral agent and administrative agent, and the lenders party thereto
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/1/2014
|
|
|
|
10.27
|
|
Amendment No.3, dated February 13, 2015
, among, inter alia, Platform, Holdings, MacDermid, the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
2/17/2015
|
|
|
|
10.28
|
|
Amendment No. 4, dated December 3, 2015
, among, inter alia, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
12/4/2015
|
|
|
|
10.29
|
|
Amendment No. 5, dated October 14, 2016
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/17/2016
|
|
|
|
10.30
|
|
Amendment No. 6, dated December 6, 2016
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
12/7/2016
|
|
|
|
10.31
|
|
Amendment No. 7, dated April 18, 2017
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
4/18/2017
|
|
|
|
10.32
|
|
Amendment No. 8, dated October 3, 2017
, among, inter alios, Platform, MacDermid, the subsidiaries of the borrowers from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
10/3/2017
|
|
|
|
|
|
|
|
Incorporated by Reference
|
|
Included in this 2017 Annual Report
|
||||||
|
Exhibit
Nb.
|
|
Exhibit Description
|
|
Form
|
|
File Nb.
|
|
Exhibit
Nb.
|
|
Filing Date
|
|
|
|
10.33
|
|
Amended and Restated Pledge and Security Agreement, amended and restated as of October 31, 2013
,
among Platform, MacDermid Holdings, LLC, MacDermid, Incorporated and the subsidiaries of the borrowers from time to time parties thereto in favor of Barclays Bank PLC, as collateral agent
|
|
10-K
|
|
001-36272
|
|
10.25
|
|
3/31/2014
|
|
|
|
10.34
|
|
|
S-4/A
|
|
333-192778
|
|
10.14
|
|
1/2/2014
|
|
|
|
|
10.35
|
|
Advisory Services Agreement, dated October 31, 2013
, by and between Platform Specialty Products Corporation and Mariposa Capital, LLC
|
|
S-4/A
|
|
333-192778
|
|
10.15
|
|
1/2/2014
|
|
|
|
10.36
|
|
Letter Agreement with respect to Supplemental Executive Retirement Plan payment, dated as of October 29, 2013
, between Platform Acquisition Holdings Limited and Daniel H. Leever
|
|
S-4/A
|
|
333-192778
|
|
10.16
|
|
1/2/2014
|
|
|
|
10.37
|
|
|
S-4/A
|
|
333-192778
|
|
10.17
|
|
1/2/2014
|
|
|
|
|
10.38
|
|
Registration Rights Agreement, dated as of May 20, 2014
, between Platform Specialty, the placement agents thereto and the Investors stated therein
|
|
8-K
|
|
001-36272
|
|
10.1
|
|
5/21/2014
|
|
|
|
10.39
|
|
|
8-K
|
|
001-36272
|
|
10.3
|
|
10/8/2014
|
|
|
|
|
14.1
|
|
|
10-K
|
|
001-36272
|
|
14.1
|
|
3/31/2014
|
|
|
|
|
21.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
31.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
31.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
32.1*
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.CAL
|
|
XBRL Extension Calculation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
|
|
|
|
|
|
X
|
|
*
|
|
Furnished herewith.
|
|
†
|
|
This Exhibit represents a management contract or a compensatory plan.
|
|
|
|
|
PLATFORM SPECIALTY PRODUCTS CORPORATION
|
|||
|
|
|
|
|
|||
|
|
|
|
By:
|
|
/s/ John P. Connolly
|
|
|
|
|
|
|
|
Name: John P. Connolly
|
|
|
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
|
Date:
|
|
February 28, 2018
|
|
|
Signature
|
|
Title
|
Date
|
|
/s/ Rakesh Sachdev
|
|
Director and Chief Executive Officer
|
February 28, 2018
|
|
Rakesh Sachdev
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ John P. Connolly
|
|
Chief Financial Officer
|
February 28, 2018
|
|
John P. Connolly
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Martin E. Franklin
|
|
Chairman of the Board
|
February 28, 2018
|
|
Martin E. Franklin
|
|
|
|
|
|
|
|
|
|
/s/ Ian G.H. Ashken
|
|
Director
|
February 28, 2018
|
|
Ian G.H. Ashken
|
|
|
|
|
|
|
|
|
|
/s/ Nicolas Berggruen
|
|
Director
|
February 28, 2018
|
|
Nicolas Berggruen
|
|
|
|
|
|
|
|
|
|
/s/ Michael F. Goss
|
|
Director
|
February 28, 2018
|
|
Michael F. Goss
|
|
|
|
|
|
|
|
|
|
/s/ Ryan Israel
|
|
Director
|
February 28, 2018
|
|
Ryan Israel
|
|
|
|
|
|
|
|
|
|
/s / E. Stanley O’Neal
|
|
Director
|
February 28, 2018
|
|
E. Stanley O’Neal
|
|
|
|
|
|
|
Page
|
|
|
|
|
|
|
||
|
|
|
|
|
Consolidated Financial Statements:
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2017 and 2016
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
Financial Statement Schedule:
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31, 2017, 2016 and 2015
|
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Net sales
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
Cost of sales
|
|
2,186.9
|
|
|
2,078.2
|
|
|
1,550.4
|
|
|||
|
Gross profit
|
|
1,589.0
|
|
|
1,507.7
|
|
|
991.9
|
|
|||
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|||
|
Selling, technical, general and administrative
|
|
1,109.3
|
|
|
1,123.3
|
|
|
857.5
|
|
|||
|
Research and development
|
|
98.4
|
|
|
84.4
|
|
|
62.8
|
|
|||
|
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
|
Total operating expenses
|
|
1,367.7
|
|
|
1,254.3
|
|
|
920.3
|
|
|||
|
Operating profit
|
|
221.3
|
|
|
253.4
|
|
|
71.6
|
|
|||
|
Other (expense) income:
|
|
|
|
|
|
|
|
|
|
|||
|
Interest expense, net
|
|
(341.6
|
)
|
|
(375.7
|
)
|
|
(213.9
|
)
|
|||
|
Foreign exchange loss
|
|
(107.5
|
)
|
|
(14.1
|
)
|
|
(43.4
|
)
|
|||
|
Other (expense) income, net
|
|
(61.2
|
)
|
|
88.3
|
|
|
(43.6
|
)
|
|||
|
Total other expense
|
|
(510.3
|
)
|
|
(301.5
|
)
|
|
(300.9
|
)
|
|||
|
Loss before income taxes and non-controlling interests
|
|
(289.0
|
)
|
|
(48.1
|
)
|
|
(229.3
|
)
|
|||
|
Income tax expense
|
|
(6.6
|
)
|
|
(28.6
|
)
|
|
(75.1
|
)
|
|||
|
Net loss
|
|
(295.6
|
)
|
|
(76.7
|
)
|
|
(304.4
|
)
|
|||
|
Net (income) loss attributable to the non-controlling interests
|
|
(0.6
|
)
|
|
3.0
|
|
|
(4.2
|
)
|
|||
|
Net loss attributable to stockholders
|
|
(296.2
|
)
|
|
(73.7
|
)
|
|
(308.6
|
)
|
|||
|
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
32.9
|
|
|
—
|
|
|||
|
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
|
Loss per share
|
|
|
|
|
|
|
|
|
|
|||
|
Basic
|
|
$
|
(1.04
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(1.52
|
)
|
|
Diluted
|
|
$
|
(1.04
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(1.52
|
)
|
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
|
|
|
|||
|
Basic
|
|
286.1
|
|
|
243.3
|
|
|
203.2
|
|
|||
|
Diluted
|
|
286.1
|
|
|
272.3
|
|
|
203.2
|
|
|||
|
|
|
Year Ended December 31,
|
||||||||||
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
$
|
(304.4
|
)
|
|
|
|
|
|
|
|
|
||||||
|
Other comprehensive income (loss)
|
|
|
|
|
|
|
|
|
|
|||
|
Foreign currency translation adjustments
|
|
241.1
|
|
|
204.6
|
|
|
(777.1
|
)
|
|||
|
Pension and post-retirement plans:
|
|
|
|
|
|
|
|
|
|
|||
|
Other comprehensive income (loss), net of tax (expense) benefit of $(2.2), ($0.9) and $3.2 for 2017, 2016 and 2015, respectively
|
|
2.5
|
|
|
7.5
|
|
|
(11.4
|
)
|
|||
|
Reclassifications, net of tax expense of $2.1 for 2017, $0.0 for 2016 and 2015
|
|
8.4
|
|
|
—
|
|
|
—
|
|
|||
|
Total pension and post-retirement plans
|
|
10.9
|
|
|
7.5
|
|
|
(11.4
|
)
|
|||
|
Unrealized (loss) gain on available for sale securities:
|
|
|
|
|
|
|
|
|
|
|||
|
Other comprehensive (loss) income, net of tax benefit (expense) of $0.4, $0.6 and ($0.6) for 2017, 2016 and 2015, respectively
|
|
(2.2
|
)
|
|
(0.8
|
)
|
|
1.1
|
|
|||
|
Reclassifications, net of tax expense of $0.0 for 2017, 2016 and 2015
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|||
|
Total unrealized (loss) gain on available for sale securities
|
|
(1.7
|
)
|
|
(0.8
|
)
|
|
1.1
|
|
|||
|
Derivative financial instrument revaluation:
|
|
|
|
|
|
|
|
|
|
|||
|
Other comprehensive loss before reclassifications, net of tax (expense) benefit of $(4.3), $0.0 and $4.4 for 2017, 2016 and 2015, respectively
|
|
(4.6
|
)
|
|
(9.6
|
)
|
|
(8.1
|
)
|
|||
|
Reclassifications, net of tax expense of $0.0 for 2017, 2016 and 2015
|
|
10.4
|
|
|
11.9
|
|
|
—
|
|
|||
|
Total unrealized gain (loss) arising on qualified hedging derivatives
|
|
5.8
|
|
|
2.3
|
|
|
(8.1
|
)
|
|||
|
Other comprehensive income (loss)
|
|
256.1
|
|
|
213.6
|
|
|
(795.5
|
)
|
|||
|
|
|
|
|
|
|
|
||||||
|
Comprehensive (loss) income
|
|
(39.5
|
)
|
|
136.9
|
|
|
(1,099.9
|
)
|
|||
|
Comprehensive (income) loss attributable to the non-controlling interests
|
|
(4.3
|
)
|
|
1.0
|
|
|
35.8
|
|
|||
|
Comprehensive income (loss) attributable to stockholders
|
|
$
|
(43.8
|
)
|
|
$
|
137.9
|
|
|
$
|
(1,064.1
|
)
|
|
|
|
December 31,
|
||||||
|
|
|
2017
|
|
2016
|
||||
|
Assets
|
|
|
|
|
||||
|
Cash & cash equivalents
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
Accounts receivable, net
|
|
1,156.0
|
|
|
1,054.8
|
|
||
|
Inventories
|
|
490.4
|
|
|
416.4
|
|
||
|
Prepaid expenses
|
|
42.8
|
|
|
71.3
|
|
||
|
Other current assets
|
|
173.6
|
|
|
106.1
|
|
||
|
Total current assets
|
|
2,340.6
|
|
|
2,071.2
|
|
||
|
Property, plant & equipment, net
|
|
452.3
|
|
|
460.5
|
|
||
|
Goodwill
|
|
4,201.2
|
|
|
4,178.9
|
|
||
|
Intangible assets, net
|
|
3,137.3
|
|
|
3,233.3
|
|
||
|
Other assets
|
|
121.0
|
|
|
110.2
|
|
||
|
Total assets
|
|
$
|
10,252.4
|
|
|
$
|
10,054.1
|
|
|
Liabilities & stockholders' equity
|
|
|
|
|
|
|
||
|
Accounts payable
|
|
$
|
461.8
|
|
|
$
|
383.6
|
|
|
Current installments of long-term debt and revolving credit facilities
|
|
38.9
|
|
|
116.1
|
|
||
|
Accrued expenses and other current liabilities
|
|
591.1
|
|
|
583.0
|
|
||
|
Total current liabilities
|
|
1,091.8
|
|
|
1,082.7
|
|
||
|
Debt and capital lease obligations
|
|
5,440.6
|
|
|
5,122.9
|
|
||
|
Pension and post-retirement benefits
|
|
69.0
|
|
|
73.8
|
|
||
|
Deferred income taxes
|
|
579.6
|
|
|
663.2
|
|
||
|
Contingent consideration
|
|
79.2
|
|
|
75.8
|
|
||
|
Other liabilities
|
|
132.2
|
|
|
145.9
|
|
||
|
Total liabilities
|
|
7,392.4
|
|
|
7,164.3
|
|
||
|
Commitments and contingencies (Note 18)
|
|
|
|
|
|
|
||
|
Stockholders' equity
|
|
|
|
|
|
|
||
|
Preferred stock - Series A
|
|
—
|
|
|
—
|
|
||
|
Common stock, 400.0 shares authorized (2017: 287.4 shares issued; 2016: 284.2 shares issued)
|
|
2.9
|
|
|
2.8
|
|
||
|
Treasury stock (2017: 0.0 shares; 2016: 0.0 shares)
|
|
(0.1
|
)
|
|
—
|
|
||
|
Additional paid-in capital
|
|
4,032.0
|
|
|
3,981.3
|
|
||
|
Accumulated deficit
|
|
(869.7
|
)
|
|
(573.5
|
)
|
||
|
Accumulated other comprehensive loss
|
|
(422.0
|
)
|
|
(674.5
|
)
|
||
|
Total stockholders' equity
|
|
2,743.1
|
|
|
2,736.1
|
|
||
|
Non-controlling interests
|
|
116.9
|
|
|
153.7
|
|
||
|
Total equity
|
|
2,860.0
|
|
|
2,889.8
|
|
||
|
Total liabilities and stockholders' equity
|
|
$
|
10,252.4
|
|
|
$
|
10,054.1
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Cash flows from operating activities:
|
|
|
|
|
|
|
||||||
|
Net loss
|
|
$
|
(295.6
|
)
|
|
$
|
(76.7
|
)
|
|
$
|
(304.4
|
)
|
|
Reconciliations of net loss to net cash flows provided by operating activities:
|
|
|
|
|
|
|
|
|
|
|||
|
Depreciation and amortization
|
|
354.2
|
|
|
342.3
|
|
|
251.0
|
|
|||
|
Deferred income taxes
|
|
(126.6
|
)
|
|
(57.4
|
)
|
|
(45.5
|
)
|
|||
|
Amortization of inventory step-up
|
|
—
|
|
|
11.7
|
|
|
76.5
|
|
|||
|
Foreign exchange loss
|
|
114.0
|
|
|
43.8
|
|
|
97.3
|
|
|||
|
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
|
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
|
Other, net
|
|
89.9
|
|
|
85.2
|
|
|
36.6
|
|
|||
|
Changes in assets and liabilities, net of acquisitions:
|
|
|
|
|
|
|
|
|
|
|||
|
Accounts receivable
|
|
(53.1
|
)
|
|
(18.9
|
)
|
|
66.7
|
|
|||
|
Inventory
|
|
(30.3
|
)
|
|
70.4
|
|
|
(7.3
|
)
|
|||
|
Accounts payable
|
|
49.8
|
|
|
(67.3
|
)
|
|
83.2
|
|
|||
|
Accrued expenses
|
|
(9.2
|
)
|
|
25.4
|
|
|
51.5
|
|
|||
|
Prepaid expenses and other current assets
|
|
(27.0
|
)
|
|
(0.4
|
)
|
|
(20.3
|
)
|
|||
|
Other assets and liabilities
|
|
(44.0
|
)
|
|
(116.9
|
)
|
|
35.6
|
|
|||
|
Net cash flows provided by operating activities
|
|
182.1
|
|
|
184.8
|
|
|
320.9
|
|
|||
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
|
|||
|
Capital expenditures
|
|
(59.4
|
)
|
|
(56.3
|
)
|
|
(47.9
|
)
|
|||
|
Investment in registrations of products
|
|
(40.5
|
)
|
|
(36.4
|
)
|
|
(34.4
|
)
|
|||
|
Proceeds from disposal of property, plant and equipment
|
|
17.5
|
|
|
20.6
|
|
|
25.8
|
|
|||
|
Acquisition of business, net of cash acquired
|
|
(0.5
|
)
|
|
1.3
|
|
|
(4,600.3
|
)
|
|||
|
Restricted cash
|
|
(5.2
|
)
|
|
(0.5
|
)
|
|
599.7
|
|
|||
|
Note receivable
|
|
—
|
|
|
—
|
|
|
(125.0
|
)
|
|||
|
Settlement of foreign exchange contracts in connection with acquisition
|
|
—
|
|
|
—
|
|
|
(73.1
|
)
|
|||
|
Other, net
|
|
(4.5
|
)
|
|
(3.4
|
)
|
|
(1.3
|
)
|
|||
|
Net cash flows used in investing activities
|
|
(92.6
|
)
|
|
(74.7
|
)
|
|
(4,256.5
|
)
|
|||
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|||
|
Debt proceeds, net of discount and premium
|
|
4,142.7
|
|
|
3,300.9
|
|
|
3,921.8
|
|
|||
|
Repayments of borrowings
|
|
(4,122.1
|
)
|
|
(3,340.1
|
)
|
|
(283.7
|
)
|
|||
|
Change in lines of credit, net
|
|
(58.8
|
)
|
|
54.0
|
|
|
(12.4
|
)
|
|||
|
Proceeds from issuance of common stock, net
|
|
1.4
|
|
|
391.5
|
|
|
469.5
|
|
|||
|
Change in on-balance sheet factoring arrangements
|
|
(3.5
|
)
|
|
(44.1
|
)
|
|
(3.9
|
)
|
|||
|
Payment of financing fees
|
|
(13.8
|
)
|
|
(1.1
|
)
|
|
(87.0
|
)
|
|||
|
Settlement of Series B Convertible Preferred Stock
|
|
—
|
|
|
(460.0
|
)
|
|
—
|
|
|||
|
Other, net
|
|
(13.3
|
)
|
|
(3.3
|
)
|
|
(3.1
|
)
|
|||
|
Net cash flows (used in) provided by financing activities
|
|
(67.4
|
)
|
|
(102.2
|
)
|
|
4,001.2
|
|
|||
|
Effect of exchange rate changes on cash and cash equivalents
|
|
33.1
|
|
|
(17.5
|
)
|
|
(30.7
|
)
|
|||
|
Net increase (decrease) in cash and cash equivalents
|
|
55.2
|
|
|
(9.6
|
)
|
|
34.9
|
|
|||
|
Cash and cash equivalents at beginning of period
|
|
422.6
|
|
|
432.2
|
|
|
397.3
|
|
|||
|
Cash and cash equivalents at end of period
|
|
$
|
477.8
|
|
|
$
|
422.6
|
|
|
$
|
432.2
|
|
|
|
|
|
|
|
|
|
||||||
|
Supplemental disclosure information:
|
|
|
|
|
|
|
||||||
|
Cash paid for interest
|
|
$
|
322.8
|
|
|
$
|
360.1
|
|
|
$
|
147.6
|
|
|
Cash paid for income taxes
|
|
$
|
145.0
|
|
|
$
|
121.2
|
|
|
$
|
73.3
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Treasury Stock
|
|
Accumulated Deficit
|
|
Accumulated other Comprehensive (Loss) Income
|
|
Total Stockholders' Equity
|
|
Non- controlling Interest
|
|
Total Equity
|
|||||||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||||
|
Balance at December 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
284,221,168
|
|
|
$
|
2.8
|
|
|
$
|
3,981.3
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(573.5
|
)
|
|
$
|
(674.5
|
)
|
|
$
|
2,736.1
|
|
|
$
|
153.7
|
|
|
$
|
2,889.8
|
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(296.2
|
)
|
|
—
|
|
|
(296.2
|
)
|
|
0.6
|
|
|
(295.6
|
)
|
|||||||||
|
Other comprehensive income, net of taxes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
252.5
|
|
|
252.5
|
|
|
3.6
|
|
|
256.1
|
|
|||||||||
|
Exercise/ vesting of share based compensation
|
—
|
|
|
—
|
|
|
122,769
|
|
|
—
|
|
|
0.1
|
|
|
6,618
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
2,923,436
|
|
|
0.1
|
|
|
35.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
35.7
|
|
|
(35.7
|
)
|
|
—
|
|
|||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
138,566
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1.3
|
|
|
—
|
|
|
1.3
|
|
|||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
|
|
—
|
|
|
11.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
11.7
|
|
|
—
|
|
|
11.7
|
|
||||||||||
|
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2.0
|
|
|
(5.3
|
)
|
|
(3.3
|
)
|
|||||||||
|
Balance at December 31, 2017
|
2,000,000
|
|
|
$
|
—
|
|
|
287,405,939
|
|
|
$
|
2.9
|
|
|
$
|
4,032.0
|
|
|
6,618
|
|
|
$
|
(0.1
|
)
|
|
$
|
(869.7
|
)
|
|
$
|
(422.0
|
)
|
|
$
|
2,743.1
|
|
|
$
|
116.9
|
|
|
$
|
2,860.0
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional Paid-in Capital
|
|
Treasury Stock
|
|
Accumulated Deficit
|
|
Accumulated other Comprehensive (Loss) Income
|
|
Total Stockholders' Equity
|
|
Non- controlling Interest
|
|
Total Equity
|
|||||||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||||
|
Balance at December 31, 2015
|
2,000,000
|
|
|
$
|
—
|
|
|
229,464,157
|
|
|
$
|
2.3
|
|
|
$
|
3,520.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(532.7
|
)
|
|
$
|
(886.1
|
)
|
|
$
|
2,103.9
|
|
|
$
|
169.4
|
|
|
$
|
2,273.3
|
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(73.7
|
)
|
|
—
|
|
|
(73.7
|
)
|
|
(3.0
|
)
|
|
(76.7
|
)
|
|||||||||
|
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
211.6
|
|
|
211.6
|
|
|
2.0
|
|
|
213.6
|
|
|||||||||
|
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
7,642
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
325,431
|
|
|
—
|
|
|
3.8
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
(3.8
|
)
|
|
—
|
|
|||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
136,060
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7.4
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
7.4
|
|
|
—
|
|
|
7.4
|
|
|||||||||
|
Issuance of common stock at $8.25 per share in the September 2016 Equity Offering
|
—
|
|
|
—
|
|
|
48,787,878
|
|
|
0.5
|
|
|
402.0
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
402.5
|
|
|
—
|
|
|
402.5
|
|
|||||||||
|
Issuance costs in connection with the September 2016 Equity Offering
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11.9
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(11.9
|
)
|
|
—
|
|
|
(11.9
|
)
|
|||||||||
|
Series B Convertible Preferred Stock settlement
|
—
|
|
|
—
|
|
|
5,500,000
|
|
|
—
|
|
|
54.9
|
|
|
—
|
|
|
—
|
|
|
32.9
|
|
|
—
|
|
|
87.8
|
|
|
—
|
|
|
87.8
|
|
|||||||||
|
Changes in non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
—
|
|
|
|
|
—
|
|
|
—
|
|
|
3.8
|
|
|
(10.9
|
)
|
|
(7.1
|
)
|
||||||||||
|
Balance at December 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
284,221,168
|
|
|
$
|
2.8
|
|
|
$
|
3,981.3
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(573.5
|
)
|
|
$
|
(674.5
|
)
|
|
$
|
2,736.1
|
|
|
$
|
153.7
|
|
|
$
|
2,889.8
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
Additional
Paid-in Capital |
|
Treasury Stock
|
|
Accumulated
Deficit |
|
Accumulated
Other Comprehensive Loss |
|
Total
Stockholders' Equity |
|
Non-
controlling Interests |
|
Total Equity
|
|||||||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|||||||||||||||||||||||||||||||||
|
Balance at December 31, 2014
|
2,000,000
|
|
|
$
|
—
|
|
|
182,066,980
|
|
|
$
|
1.9
|
|
|
$
|
2,812.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(224.1
|
)
|
|
$
|
(130.6
|
)
|
|
$
|
2,459.6
|
|
|
$
|
93.0
|
|
|
$
|
2,552.6
|
|
|
Net (loss) income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(308.6
|
)
|
|
—
|
|
|
(308.6
|
)
|
|
4.2
|
|
|
(304.4
|
)
|
|||||||||
|
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(755.5
|
)
|
|
(755.5
|
)
|
|
(40.0
|
)
|
|
(795.5
|
)
|
|||||||||
|
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on December 31, 2014
|
—
|
|
|
—
|
|
|
10,050,290
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
578,874
|
|
|
—
|
|
|
6.6
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6.6
|
|
|
(6.6
|
)
|
|
—
|
|
|||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
44,361
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
0.7
|
|
|||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
|||||||||
|
Acquisition of non-controlling interest with Arysta Acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
125.4
|
|
|
125.4
|
|
|||||||||
|
Issuance of common stock at $26.50 per share in June 2015 Equity Offering
|
—
|
|
|
—
|
|
|
18,226,414
|
|
|
0.2
|
|
|
482.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
482.9
|
|
|
—
|
|
|
482.9
|
|
|||||||||
|
Issuance costs in connection with June 2015 Equity Offering
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15.0
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15.0
|
)
|
|
—
|
|
|
(15.0
|
)
|
|||||||||
|
Issuance of common shares to non-employee
|
—
|
|
|
—
|
|
|
2,500
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|||||||||
|
Acquisition of remaining interest in Arysta Colombia
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(3.3
|
)
|
|
(3.3
|
)
|
|||||||||
|
Issuance of common shares at $12.56 per share in connection with Alent acquisition on December 1, 2015
|
—
|
|
|
—
|
|
|
18,419,738
|
|
|
0.2
|
|
|
231.2
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
231.4
|
|
|
—
|
|
|
231.4
|
|
|||||||||
|
Sale of 50.65% ownership in Arysta Toyo Green Co LTD, including maintenance subsidiary
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.7
|
)
|
|
(1.7
|
)
|
|||||||||
|
Distribution to non-controlling interests
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(1.6
|
)
|
|
(1.6
|
)
|
|||||||||
|
Balance at December 31, 2015
|
2,000,000
|
|
|
$
|
—
|
|
|
229,464,157
|
|
|
$
|
2.3
|
|
|
$
|
3,520.4
|
|
|
—
|
|
|
$
|
—
|
|
|
$
|
(532.7
|
)
|
|
$
|
(886.1
|
)
|
|
$
|
2,103.9
|
|
|
$
|
169.4
|
|
|
$
|
2,273.3
|
|
|
|
|
Average useful life
(in years)
|
||||
|
Buildings and building improvements
|
|
5
|
|
to
|
|
20
|
|
Machinery, equipment and fixtures
|
|
3
|
|
to
|
|
15
|
|
Computer hardware and software
|
|
3
|
|
to
|
|
7
|
|
Furniture and automobiles
|
|
3
|
|
to
|
|
7
|
|
Leasehold improvements
|
|
Lesser of useful life
or lease term
|
||||
|
•
|
Valuation Techniques
- the Company uses a discounted cash flow analysis, which requires assumptions about short and long-term net cash flows, growth rates, as well as discount rates. Additionally, it considers guideline company and guideline transaction information, where available, to aid in the valuation of the reporting units.
|
|
•
|
Growth Assumptions
- Multi-year financial forecasts are developed for each reporting unit by considering several key business drivers such as new business initiatives, client service and retention standards, market share changes, historical performance, and industry and economic trends, among other considerations.
|
|
•
|
Discount Rate Assumptions
- Discount rates are estimated based on the WACC, which combines the required return on equity and considers the risk-free interest rate, market risk premium, small stock risk premium and a company specific risk premium, with the cost of debt, based on rated corporate bonds, adjusted using an income tax factor.
|
|
•
|
Estimated Fair Value and Sensitivitie
s - The estimated fair value of each reporting unit is derived from the valuation techniques described above. The estimated fair value of each reporting unit is analyzed in relation to numerous market and historical factors, including current economic and market conditions, company-specific growth opportunities and guideline company information.
|
|
•
|
Level 1 – inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
|
•
|
Level 2 – inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model-derived valuations whose inputs are observable or whose significant valuation drivers are observable.
|
|
•
|
Level 3 – inputs to valuation models are unobservable and/or reflect the Company’s market assumptions.
|
|
•
|
Arrangements whereby the Company sells trade receivables to third parties without recourse and receives beneficial interests for a portion of these receivables, the proceeds of which are currently included in “Operating Activities” in the Condensed Consolidated Statements of Cash Flows. Under the new guidance, approximately
$69.0 million
and
$3.9 million
of beneficial interests will be disclosed as a non-cash activity, with cash receipts of approximately
$44.3 million
and
$3.4 million
classified as cash inflows from "Investing Activities" in the Consolidated Statements of Cash Flows for 2017 and 2016, respectively.
|
|
•
|
Cash payments for debt prepayments and debt extinguishment costs of approximately
$8.8 million
and
$8.4 million
will be reclassified from "Operating Activities" to "Financing Activities" in the Consolidated Statements of Cash Flows for 2017 and 2016, respectively.
|
|
($ amounts in millions)
|
|
Year of Acquisition
|
|
Net Sales
|
|
Net Income (Loss)
|
||||
|
OMG Malaysia
|
|
2016
|
|
$
|
30.9
|
|
|
$
|
3.2
|
|
|
Alent
|
|
2015
|
|
70.8
|
|
|
(12.4
|
)
|
||
|
OMG
|
|
2015
|
|
20.7
|
|
|
(0.4
|
)
|
||
|
Arysta
|
|
2015
|
|
1,197.0
|
|
|
(86.7
|
)
|
||
|
($ amounts in millions)
|
|
OMG Malaysia
|
||
|
Consideration
|
|
|
||
|
Cash, net
|
|
$
|
(1.3
|
)
|
|
Note receivable settlement
|
|
125.0
|
|
|
|
Total consideration
|
|
$
|
123.7
|
|
|
|
|
|
||
|
Acquisition costs
|
|
$
|
0.5
|
|
|
|
|
|
||
|
Identifiable assets acquired and liabilities assumed
|
|
|
||
|
Accounts receivable
|
|
$
|
4.3
|
|
|
Inventories
|
|
6.4
|
|
|
|
Other current assets
|
|
0.2
|
|
|
|
Property, plant and equipment
|
|
4.7
|
|
|
|
Identifiable intangible assets
|
|
43.9
|
|
|
|
Current liabilities
|
|
(3.5
|
)
|
|
|
Non-current deferred tax liability
|
|
(11.3
|
)
|
|
|
Total identifiable net assets
|
|
44.7
|
|
|
|
Goodwill
|
|
79.0
|
|
|
|
Total purchase price
|
|
$
|
123.7
|
|
|
|
|
OMG Malaysia
|
||||
|
($ amounts in millions)
|
|
Fair Value
|
|
Weighted average useful life (years)
|
||
|
Customer lists
|
|
$
|
41.0
|
|
|
15.0
|
|
Developed technology
|
|
2.9
|
|
|
5.0
|
|
|
Total
|
|
$
|
43.9
|
|
|
14.3
|
|
|
|
Year Ended December 31,
|
||
|
($ amounts in millions)
|
|
2015
|
||
|
Pro forma net sales
|
|
$
|
3,582.4
|
|
|
Pro forma net loss attributable to stockholders
|
|
(328.1
|
)
|
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
|
Total accounts receivable, net
|
|
$
|
1,157.7
|
|
|
$
|
1,058.0
|
|
|
Non-current accounts receivable, net
|
|
(1.7
|
)
|
|
(3.2
|
)
|
||
|
Current accounts receivable, net
|
|
$
|
1,156.0
|
|
|
$
|
1,054.8
|
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
|
Finished goods
|
|
$
|
328.9
|
|
|
$
|
273.8
|
|
|
Work in process
|
|
28.8
|
|
|
37.1
|
|
||
|
Raw materials and supplies
|
|
149.8
|
|
|
135.9
|
|
||
|
Total inventory, net
|
|
507.5
|
|
|
446.8
|
|
||
|
Non-current inventory, net
|
|
(17.0
|
)
|
|
(30.4
|
)
|
||
|
Current inventory, net
|
|
$
|
490.4
|
|
|
$
|
416.4
|
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
|
Land and leasehold improvements
|
|
$
|
108.8
|
|
|
$
|
109.2
|
|
|
Buildings and improvements
|
|
149.8
|
|
|
141.8
|
|
||
|
Machinery, equipment, fixtures, and software
|
|
344.6
|
|
|
293.2
|
|
||
|
Construction in process
|
|
34.3
|
|
|
36.7
|
|
||
|
Total property, plant and equipment
|
|
637.5
|
|
|
580.9
|
|
||
|
Accumulated depreciation
|
|
(185.2
|
)
|
|
(120.4
|
)
|
||
|
Property, plant and equipment, net
|
|
$
|
452.3
|
|
|
$
|
460.5
|
|
|
($ amounts in millions)
|
|
Performance Solutions
|
|
Agricultural Solutions
|
|
Total
|
||||||
|
Balance, December 31, 2015
|
|
|
|
|
|
|
||||||
|
Goodwill
|
|
$
|
2,147.2
|
|
|
$
|
1,874.7
|
|
|
$
|
4,021.9
|
|
|
Accumulated impairment losses
|
|
—
|
|
|
—
|
|
|
—
|
|
|||
|
|
|
2,147.2
|
|
|
1,874.7
|
|
|
4,021.9
|
|
|||
|
Addition from acquisitions
|
|
66.9
|
|
|
—
|
|
|
66.9
|
|
|||
|
Purchase accounting adjustments
|
|
29.7
|
|
|
15.1
|
|
|
44.8
|
|
|||
|
Impairment write-off
|
|
(46.6
|
)
|
|
—
|
|
|
(46.6
|
)
|
|||
|
Foreign currency translation and other
|
|
(64.8
|
)
|
|
156.7
|
|
|
91.9
|
|
|||
|
Balance, December 31, 2016
|
|
|
|
|
|
|
||||||
|
Goodwill, gross
|
|
2,179.0
|
|
|
2,046.5
|
|
|
4,225.5
|
|
|||
|
Accumulated impairment losses
|
|
(46.6
|
)
|
|
—
|
|
|
(46.6
|
)
|
|||
|
|
|
2,132.4
|
|
|
2,046.5
|
|
|
4,178.9
|
|
|||
|
Impairment write-off
|
|
—
|
|
|
(160.0
|
)
|
|
(160.0
|
)
|
|||
|
Foreign currency translation and other
|
|
120.2
|
|
|
62.1
|
|
|
182.3
|
|
|||
|
Balance, December 31, 2017
|
|
|
|
|
|
|
||||||
|
Goodwill, gross
|
|
2,299.2
|
|
|
2,108.6
|
|
|
4,407.8
|
|
|||
|
Accumulated impairment losses
|
|
(46.6
|
)
|
|
(160.0
|
)
|
|
(206.6
|
)
|
|||
|
|
|
$
|
2,252.6
|
|
|
$
|
1,948.6
|
|
|
$
|
4,201.2
|
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||||||||||
|
($ amounts in millions)
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Book Value
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Net Book Value
|
||||||||||||
|
Customer lists
|
|
$
|
1,303.3
|
|
|
$
|
(263.5
|
)
|
|
$
|
1,039.8
|
|
|
$
|
1,245.9
|
|
|
$
|
(174.5
|
)
|
|
$
|
1,071.4
|
|
|
Developed technology
(1)
|
|
2,250.7
|
|
|
(557.0
|
)
|
|
1,693.7
|
|
|
2,022.1
|
|
|
(254.9
|
)
|
|
1,767.2
|
|
||||||
|
Trade names
|
|
30.3
|
|
|
(13.8
|
)
|
|
16.5
|
|
|
25.1
|
|
|
(8.2
|
)
|
|
16.9
|
|
||||||
|
Non-compete agreement
|
|
2.8
|
|
|
(1.3
|
)
|
|
1.5
|
|
|
1.9
|
|
|
(1.1
|
)
|
|
0.8
|
|
||||||
|
Total
|
|
$
|
3,587.1
|
|
|
$
|
(835.6
|
)
|
|
$
|
2,751.5
|
|
|
$
|
3,295.0
|
|
|
$
|
(438.7
|
)
|
|
$
|
2,856.3
|
|
|
($ amounts in millions)
|
|
Amortization Expense
|
||
|
2018
|
|
$
|
282.6
|
|
|
2019
|
|
282.4
|
|
|
|
2020
|
|
277.9
|
|
|
|
2021
|
|
269.5
|
|
|
|
2022
|
|
254.9
|
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Equity classified RSUs
|
|
$
|
10.4
|
|
|
$
|
6.5
|
|
|
$
|
0.8
|
|
|
Liability classified share-based payments
|
|
0.6
|
|
|
0.4
|
|
|
(0.1
|
)
|
|||
|
Stock options
|
|
0.8
|
|
|
0.5
|
|
|
—
|
|
|||
|
Long-term cash bonus plans
|
|
—
|
|
|
(0.1
|
)
|
|
0.1
|
|
|||
|
Total
|
|
$
|
11.8
|
|
|
$
|
7.3
|
|
|
$
|
0.8
|
|
|
|
|
|
|
|
|
|
||||||
|
Unrecognized compensation expense for awards expected to vest
|
|
$
|
22.2
|
|
|
|
|
|
||||
|
Weighted average remaining vesting period (months)
|
|
19.1
|
|
|
|
|
|
|||||
|
|
|
Total
|
|
RSUs
|
|
Stock Options
(1)
|
||||||
|
|
|
Equity
Classified
|
|
Liability
Classified
|
|
|||||||
|
Outstanding at December 31, 2016
|
|
3,003,003
|
|
|
2,117,493
|
|
|
320,312
|
|
|
565,198
|
|
|
Granted
|
|
1,373,921
|
|
|
1,117,719
|
|
|
—
|
|
|
256,202
|
|
|
Exercised/Issued
|
|
(122,769
|
)
|
|
(107,450
|
)
|
|
—
|
|
|
(15,319
|
)
|
|
Forfeited
|
|
(578,429
|
)
|
|
(503,911
|
)
|
|
(634
|
)
|
|
(73,884
|
)
|
|
Outstanding at December 31, 2017
|
|
3,675,726
|
|
|
2,623,851
|
|
|
319,678
|
|
|
732,197
|
|
|
Year of Issuance:
|
|
RSUs
|
|
Weighted average grant date fair value
|
|
Weighted average vesting period (months)
|
|||
|
2017
|
|
1,117,719
|
|
|
$
|
16.08
|
|
|
31.2
|
|
2016
|
|
1,754,868
|
|
|
10.85
|
|
|
33.8
|
|
|
2015
|
|
453,260
|
|
|
24.55
|
|
|
54.6
|
|
|
|
|
Year Ended December 31,
|
||
|
|
|
2017
|
|
2016
|
|
Weighted average expected term (years)
(1)
|
|
3.00
|
|
3.00
|
|
Expected volatility
(2)
|
|
52.1%
|
|
53.0%
|
|
Risk-free rate
(3)
|
|
1.50%
|
|
1.05%
|
|
(1)
|
Weighted average expected term is calculated based on the award vesting period.
|
|
(2)
|
Expected volatility is calculated based on a blend of the implied and historical equity volatility of an index of comparable companies over a period equal to the expected term.
|
|
(3)
|
Risk-free rate of return is based on an interpolation of U.S. Treasury rates to reflect an expected term of
three years
at the date of grant.
|
|
|
|
December 31, 2017
|
||||||
|
Vesting Conditions:
|
|
Outstanding
|
|
Weighted average remaining vesting period (months)
|
|
Potential additional awards
|
||
|
Service-based
|
|
931,906
|
|
|
16.9
|
|
—
|
|
|
Performance-based
|
|
947,013
|
|
|
17.7
|
|
617,020
|
|
|
Market-based
|
|
744,932
|
|
|
21.0
|
|
1,443,238
|
|
|
Total
|
|
2,623,851
|
|
|
18.4
|
|
2,060,258
|
|
|
Year of Issuance:
|
|
Stock Options
|
|
Weighted average strike price per share
|
|
Weighted average grant date fair value per share
|
|||||
|
2017
|
|
256,202
|
|
|
$
|
13.30
|
|
|
$
|
6.05
|
|
|
2016
|
|
390,198
|
|
|
8.05
|
|
|
4.35
|
|
||
|
|
|
Year Ended December 31,
|
||
|
|
|
2017
|
|
2016
|
|
Weighted average expected term (years)
(1)
|
|
6.0
|
|
6.0
|
|
Expected volatility
(2)
|
|
45.0%
|
|
53.0%
|
|
Risk-free rate
(3)
|
|
2.09%
|
|
1.52% to 1.56%
|
|
Expected dividend rate
|
|
—%
|
|
—%
|
|
(1)
|
Weighted average expected term is calculated based on the simplified method for plain vanilla options.
|
|
(2)
|
Expected volatility is calculated based on a blend of the implied and historical equity volatility of an index of comparable companies over a period equal to the expected term.
|
|
(3)
|
Risk-free rate of return is based on an interpolation of U.S. Treasury rates to reflect an expected term of
six years
at the date of grant.
|
|
|
|
Year Ended December 31,
|
||||||||||||||||||||||
|
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||||||||
|
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||
|
Pension and SERP Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Service cost
|
|
$
|
—
|
|
|
$
|
2.1
|
|
|
$
|
—
|
|
|
$
|
1.8
|
|
|
$
|
—
|
|
|
$
|
1.4
|
|
|
Interest cost on the projected benefit obligation
|
|
8.8
|
|
|
2.3
|
|
|
10.1
|
|
|
3.1
|
|
|
6.8
|
|
|
2.8
|
|
||||||
|
Expected return on plan assets
|
|
(10.1
|
)
|
|
(1.9
|
)
|
|
(11.6
|
)
|
|
(2.6
|
)
|
|
(9.9
|
)
|
|
(2.7
|
)
|
||||||
|
Amortization of prior service cost
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.6
|
|
|
—
|
|
|
—
|
|
||||||
|
Amortization of actuarial net loss
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
||||||
|
Plan curtailment
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
||||||
|
Plan settlement
|
|
—
|
|
|
10.2
|
|
|
1.7
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
||||||
|
Net periodic (benefit) cost
|
|
$
|
(1.3
|
)
|
|
$
|
13.1
|
|
|
$
|
0.2
|
|
|
$
|
3.2
|
|
|
$
|
(3.1
|
)
|
|
$
|
1.5
|
|
|
Post-retirement Medical Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Service cost
|
|
$
|
—
|
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
Interest cost on the projected benefit obligation
|
|
0.4
|
|
|
0.4
|
|
|
0.4
|
|
|
0.2
|
|
|
0.3
|
|
|
0.1
|
|
||||||
|
Amortization of net loss
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Net periodic cost
|
|
$
|
0.4
|
|
|
$
|
0.6
|
|
|
$
|
0.4
|
|
|
$
|
0.3
|
|
|
$
|
0.4
|
|
|
$
|
0.2
|
|
|
|
|
Year Ended December 31,
|
||||||||||||||||
|
|
|
2017
|
|
2016
|
|
2015
|
||||||||||||
|
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||
|
Pension and SERP Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Discount rate
|
|
4.2
|
%
|
|
2.3
|
%
|
|
4.6
|
%
|
|
2.8
|
%
|
|
4.2
|
%
|
|
2.5
|
%
|
|
Rate of compensation increase
|
|
3.5
|
%
|
|
3.3
|
%
|
|
3.5
|
%
|
|
3.3
|
%
|
|
3.5
|
%
|
|
2.9
|
%
|
|
Long-term rate of return on assets
|
|
5.9
|
%
|
|
2.3
|
%
|
|
6.5
|
%
|
|
2.9
|
%
|
|
7.4
|
%
|
|
2.5
|
%
|
|
Post-retirement Medical Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Discount rate
|
|
4.2
|
%
|
|
12.2
|
%
|
|
4.4
|
%
|
|
14.0
|
%
|
|
4.2
|
%
|
|
14.5
|
%
|
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||||||||||
|
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||||||||||
|
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||||||
|
Change in Benefit Obligation:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Beginning of period balance
|
|
$
|
213.5
|
|
|
$
|
103.0
|
|
|
$
|
230.5
|
|
|
$
|
112.7
|
|
|
$
|
9.6
|
|
|
$
|
3.1
|
|
|
$
|
9.4
|
|
|
$
|
1.4
|
|
|
Additions
|
|
—
|
|
|
0.6
|
|
|
—
|
|
|
2.7
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Service cost
|
|
—
|
|
|
2.1
|
|
|
—
|
|
|
1.8
|
|
|
—
|
|
|
0.1
|
|
|
0.1
|
|
|
0.1
|
|
||||||||
|
Plan amendments
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(6.9
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Interest cost
|
|
8.8
|
|
|
2.3
|
|
|
10.1
|
|
|
3.1
|
|
|
0.4
|
|
|
0.4
|
|
|
0.4
|
|
|
0.2
|
|
||||||||
|
Plan curtailment
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
||||||||
|
Actuarial (gain) loss due to assumption change
|
|
—
|
|
|
(1.4
|
)
|
|
—
|
|
|
14.5
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
|
0.5
|
|
||||||||
|
Actuarial loss (gain) due to plan experience
|
|
13.8
|
|
|
0.3
|
|
|
5.0
|
|
|
(2.1
|
)
|
|
0.2
|
|
|
0.9
|
|
|
0.2
|
|
|
0.6
|
|
||||||||
|
Benefits and expenses paid
|
|
(9.9
|
)
|
|
(6.5
|
)
|
|
(9.2
|
)
|
|
(6.6
|
)
|
|
(0.5
|
)
|
|
(0.2
|
)
|
|
(0.8
|
)
|
|
(0.1
|
)
|
||||||||
|
Settlement
|
|
—
|
|
|
(72.2
|
)
|
|
(22.9
|
)
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Foreign currency translation
|
|
—
|
|
|
6.1
|
|
|
—
|
|
|
(13.6
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
0.4
|
|
||||||||
|
End of period balance
|
|
$
|
226.2
|
|
|
$
|
34.2
|
|
|
$
|
213.5
|
|
|
$
|
103.0
|
|
|
$
|
9.7
|
|
|
$
|
4.5
|
|
|
$
|
9.6
|
|
|
$
|
3.1
|
|
|
Change in Plan Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Beginning of period balance
|
|
$
|
176.6
|
|
|
$
|
85.0
|
|
|
$
|
184.5
|
|
|
$
|
93.7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Additions
|
|
—
|
|
|
0.5
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Actual return on plan assets, net of expenses
|
|
29.8
|
|
|
0.5
|
|
|
17.9
|
|
|
11.3
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Employer contributions
|
|
3.1
|
|
|
1.8
|
|
|
6.2
|
|
|
2.5
|
|
|
0.5
|
|
|
0.2
|
|
|
0.5
|
|
|
0.1
|
|
||||||||
|
Employee contributions
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.3
|
|
|
—
|
|
||||||||
|
Benefits paid
|
|
(9.9
|
)
|
|
(6.5
|
)
|
|
(9.1
|
)
|
|
(6.6
|
)
|
|
(0.5
|
)
|
|
(0.2
|
)
|
|
(0.8
|
)
|
|
(0.1
|
)
|
||||||||
|
Settlement
|
|
—
|
|
|
(72.2
|
)
|
|
(22.9
|
)
|
|
(2.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Foreign currency translation
|
|
—
|
|
|
3.9
|
|
|
—
|
|
|
(13.4
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
End of period balance
|
|
$
|
199.6
|
|
|
$
|
13.0
|
|
|
$
|
176.6
|
|
|
$
|
85.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Funded Status
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Funded status of plan
|
|
$
|
(26.6
|
)
|
|
$
|
(21.2
|
)
|
|
$
|
(36.9
|
)
|
|
$
|
(18.0
|
)
|
|
$
|
(9.7
|
)
|
|
$
|
(4.5
|
)
|
|
$
|
(9.6
|
)
|
|
$
|
(3.1
|
)
|
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||
|
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||
|
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||
|
Discount rate
|
|
3.7
|
%
|
|
3.0
|
%
|
|
4.2
|
%
|
|
2.3
|
%
|
|
3.7
|
%
|
|
9.9
|
%
|
|
4.2
|
%
|
|
12.2
|
%
|
|
Rate of compensation increase
|
|
3.5
|
%
|
|
3.4
|
%
|
|
3.5
|
%
|
|
3.0
|
%
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
||||||||||||||||||||||||||||
|
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||||||||||||||||||
|
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||||||||||
|
Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Other assets
|
|
$
|
—
|
|
|
$
|
3.6
|
|
|
$
|
—
|
|
|
$
|
4.0
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Accrued expenses and other current liabilities
|
|
1.1
|
|
|
0.7
|
|
|
0.7
|
|
|
0.6
|
|
|
0.6
|
|
|
0.2
|
|
|
0.6
|
|
|
0.2
|
|
||||||||
|
Pension and post-retirement benefits
|
|
25.5
|
|
|
24.1
|
|
|
36.2
|
|
|
21.4
|
|
|
9.1
|
|
|
4.3
|
|
|
9.0
|
|
|
2.9
|
|
||||||||
|
Accumulated Other Comprehensive Income (Loss) Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Net actuarial loss
|
|
$
|
(7.0
|
)
|
|
$
|
(3.1
|
)
|
|
$
|
(12.8
|
)
|
|
$
|
(12.3
|
)
|
|
$
|
(0.8
|
)
|
|
$
|
(2.2
|
)
|
|
$
|
(0.6
|
)
|
|
$
|
(1.1
|
)
|
|
Prior service costs
|
|
(0.1
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
(0.3
|
)
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
|
N/A
|
|
||||||||
|
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
Classification
|
|
2017
|
|
2016
|
||||
|
Asset Category
|
|
|
|
|
|
|
||||
|
Domestic equities
|
|
Level 1
|
|
$
|
31.8
|
|
|
$
|
31.1
|
|
|
Foreign equities
|
|
Level 1
|
|
18.3
|
|
|
—
|
|
||
|
Mutual funds holding domestic securities
|
|
Level 1
|
|
4.0
|
|
|
5.5
|
|
||
|
U.S. Treasuries
|
|
Level 2
|
|
14.6
|
|
|
4.9
|
|
||
|
Mutual funds holding U.S. Treasury Securities
|
|
Level 1
|
|
9.2
|
|
|
12.0
|
|
||
|
Mutual funds holding fixed income securities
|
|
Level 1
|
|
74.6
|
|
|
14.6
|
|
||
|
Insurance "Buy-In" Policy
(a)
|
|
Level 3
|
|
—
|
|
|
70.2
|
|
||
|
Foreign public bonds
|
|
Level 2
|
|
5.3
|
|
|
5.1
|
|
||
|
Corporate bonds
|
|
Level 2
|
|
—
|
|
|
1.2
|
|
||
|
Cash and cash equivalents
|
|
Level 1
|
|
10.1
|
|
|
15.1
|
|
||
|
Sub-Total
|
|
|
|
167.9
|
|
|
159.7
|
|
||
|
Assets using net asset value (or NAV) as a practical expedient
|
|
|
|
44.7
|
|
|
101.9
|
|
||
|
Total
|
|
|
|
$
|
212.6
|
|
|
$
|
261.6
|
|
|
(a)
|
This category represents assets in the U.K. Pension Plan invested in insurance contract with PIC in connection with the “Buy-In” of the U.K. Pension Plan, which was transferred to PIC, as of December 31, 2017.
|
|
|
|
Pension and SERP Benefits
|
|
Post-retirement Medical Benefits
|
|
Total
|
||||||||||
|
($ amounts in millions)
|
|
Domestic
|
|
Foreign
|
||||||||||||
|
2018
|
|
$
|
12.0
|
|
|
$
|
1.6
|
|
|
$
|
0.7
|
|
|
$
|
14.3
|
|
|
2019
|
|
12.0
|
|
|
1.8
|
|
|
0.8
|
|
|
14.6
|
|
||||
|
2020
|
|
12.2
|
|
|
1.7
|
|
|
0.8
|
|
|
14.7
|
|
||||
|
2021
|
|
12.1
|
|
|
1.8
|
|
|
0.8
|
|
|
14.7
|
|
||||
|
2022
|
|
12.7
|
|
|
1.9
|
|
|
0.8
|
|
|
15.4
|
|
||||
|
Subsequent five years
|
|
64.1
|
|
|
11.1
|
|
|
4.0
|
|
|
79.2
|
|
||||
|
Total
|
|
$
|
125.1
|
|
|
$
|
19.9
|
|
|
$
|
7.9
|
|
|
$
|
152.9
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Domestic
|
|
$
|
(331.0
|
)
|
|
$
|
(229.1
|
)
|
|
$
|
(290.8
|
)
|
|
Foreign
|
|
42.0
|
|
|
181.0
|
|
|
61.5
|
|
|||
|
Total
|
|
$
|
(289.0
|
)
|
|
$
|
(48.1
|
)
|
|
$
|
(229.3
|
)
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Current:
|
|
|
|
|
|
|
||||||
|
U.S.:
|
|
|
|
|
|
|
||||||
|
Federal
|
|
$
|
(1.2
|
)
|
|
$
|
0.1
|
|
|
$
|
0.7
|
|
|
State and local
|
|
1.0
|
|
|
0.4
|
|
|
(0.2
|
)
|
|||
|
Foreign
|
|
133.4
|
|
|
85.5
|
|
|
120.1
|
|
|||
|
Total current
|
|
133.2
|
|
|
86.0
|
|
|
120.6
|
|
|||
|
Deferred:
|
|
|
|
|
|
|
|
|
|
|||
|
U.S.:
|
|
|
|
|
|
|
|
|
|
|||
|
Federal
|
|
(48.7
|
)
|
|
1.9
|
|
|
6.4
|
|
|||
|
State and local
|
|
0.4
|
|
|
(0.2
|
)
|
|
(5.2
|
)
|
|||
|
Foreign
|
|
(78.3
|
)
|
|
(59.1
|
)
|
|
(46.7
|
)
|
|||
|
Total deferred
|
|
(126.6
|
)
|
|
(57.4
|
)
|
|
(45.5
|
)
|
|||
|
Income tax expense
|
|
$
|
6.6
|
|
|
$
|
28.6
|
|
|
$
|
75.1
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
U.S. federal statutory tax rate
|
|
35.0
|
%
|
|
35.0
|
%
|
|
35.0
|
%
|
|||
|
|
|
|
|
|
|
|
||||||
|
Taxes computed at U.S. statutory rate
|
|
$
|
(101.2
|
)
|
|
$
|
(16.8
|
)
|
|
$
|
(80.3
|
)
|
|
State income taxes, net of federal benefit
|
|
0.9
|
|
|
0.1
|
|
|
(3.6
|
)
|
|||
|
Foreign tax on foreign operations
|
|
(3.9
|
)
|
|
(17.2
|
)
|
|
(25.3
|
)
|
|||
|
U.S. tax on foreign operations
|
|
46.7
|
|
|
29.0
|
|
|
31.1
|
|
|||
|
Net change in reserve
|
|
(8.1
|
)
|
|
(24.1
|
)
|
|
27.5
|
|
|||
|
Change in valuation allowances
|
|
83.2
|
|
|
68.4
|
|
|
72.6
|
|
|||
|
Provision for tax on undistributed foreign earnings
|
|
(1.0
|
)
|
|
26.8
|
|
|
5.0
|
|
|||
|
Change of tax rate
|
|
(19.4
|
)
|
|
11.8
|
|
|
(1.0
|
)
|
|||
|
Impact of transaction costs
|
|
—
|
|
|
(24.5
|
)
|
|
40.5
|
|
|||
|
Settlement of Series B Convertible Preferred Stock
|
|
—
|
|
|
(34.3
|
)
|
|
—
|
|
|||
|
Goodwill impairment
|
|
53.4
|
|
|
6.2
|
|
|
—
|
|
|||
|
Provisional estimate of TCJA
|
|
(46.3
|
)
|
|
—
|
|
|
—
|
|
|||
|
Other, net
|
|
2.3
|
|
|
3.2
|
|
|
8.6
|
|
|||
|
Income tax expense
|
|
$
|
6.6
|
|
|
$
|
28.6
|
|
|
$
|
75.1
|
|
|
|
|
|
|
|
|
|
||||||
|
Effective tax rate
|
|
(2.3
|
)%
|
|
(59.5
|
)%
|
|
(32.8
|
)%
|
|||
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
|
Deferred tax assets:
|
|
|
|
|
||||
|
Net operating losses
|
|
$
|
323.0
|
|
|
$
|
355.7
|
|
|
Tax credits
|
|
62.0
|
|
|
49.2
|
|
||
|
Interest carryforward
|
|
44.4
|
|
|
34.2
|
|
||
|
Employee benefits
|
|
40.3
|
|
|
56.2
|
|
||
|
Accrued liabilities
|
|
25.9
|
|
|
50.6
|
|
||
|
Financing activities
|
|
24.3
|
|
|
3.5
|
|
||
|
Goodwill
|
|
19.5
|
|
|
31.4
|
|
||
|
Accounts receivable
|
|
19.1
|
|
|
19.8
|
|
||
|
Research and development costs
|
|
10.3
|
|
|
15.2
|
|
||
|
Inventory
|
|
4.6
|
|
|
8.5
|
|
||
|
Other
|
|
20.7
|
|
|
24.1
|
|
||
|
Total deferred tax assets
|
|
594.1
|
|
|
648.4
|
|
||
|
Valuation allowance
|
|
(391.7
|
)
|
|
(383.3
|
)
|
||
|
Total gross deferred tax assets
|
|
202.4
|
|
|
265.1
|
|
||
|
Deferred tax liabilities:
|
|
|
|
|
|
|
||
|
Intangibles
|
|
710.4
|
|
|
831.9
|
|
||
|
Plant and equipment
|
|
24.8
|
|
|
33.9
|
|
||
|
Undistributed foreign earnings
|
|
21.9
|
|
|
36.8
|
|
||
|
Other
|
|
0.4
|
|
|
6.9
|
|
||
|
Total gross deferred tax liabilities
|
|
757.5
|
|
|
909.5
|
|
||
|
Net deferred tax liability
|
|
$
|
555.1
|
|
|
$
|
644.4
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Unrecognized tax benefits at beginning of period
|
|
$
|
128.3
|
|
|
$
|
112.2
|
|
|
$
|
27.7
|
|
|
Additions based on current year tax positions
|
|
6.5
|
|
|
76.2
|
|
|
20.7
|
|
|||
|
Additions based upon prior year tax positions (including acquired uncertain tax positions)
|
|
4.0
|
|
|
1.7
|
|
|
72.2
|
|
|||
|
Reductions due to closed statutes
|
|
(6.3
|
)
|
|
(9.9
|
)
|
|
(2.9
|
)
|
|||
|
Reductions for prior period positions
|
|
(38.0
|
)
|
|
(51.9
|
)
|
|
—
|
|
|||
|
Reductions for settlements and payments
|
|
(4.2
|
)
|
|
—
|
|
|
(5.5
|
)
|
|||
|
Total unrecognized tax benefits at end of period
|
|
$
|
90.3
|
|
|
$
|
128.3
|
|
|
$
|
112.2
|
|
|
Major Jurisdictions
|
|
Open Years
|
||
|
Belgium
|
|
2010
|
|
through current
|
|
Brazil
|
|
2011
|
|
through current
|
|
Canada
|
|
2012
|
|
through current
|
|
China
|
|
2011
|
|
through current
|
|
France
|
|
2011
|
|
through current
|
|
Germany
|
|
2013
|
|
through current
|
|
Japan
|
|
2012
|
|
through current
|
|
Mexico
|
|
2012
|
|
through current
|
|
Netherlands
|
|
2013
|
|
through current
|
|
South Africa
|
|
2013
|
|
through current
|
|
Taiwan
|
|
2012
|
|
through current
|
|
United Kingdom
|
|
2008 and 2015
|
|
through current
|
|
United States
|
|
2015
|
|
through current
|
|
($ amounts in millions)
|
|
Maturity Date
|
|
Interest Rate
|
|
December 31, 2017
|
|
December 31, 2016
|
||||
|
USD Senior Notes
(1)
|
|
2022
|
|
6.50%
|
|
$
|
1,086.1
|
|
|
$
|
1,083.2
|
|
|
EUR Senior Notes
(1)
|
|
2023
|
|
6.00%
|
|
415.1
|
|
|
362.4
|
|
||
|
USD Senior Notes
(1)
|
|
2021
|
|
10.375%
|
|
—
|
|
|
489.0
|
|
||
|
USD Senior Notes
(1)
|
|
2025
|
|
5.875%
|
|
783.2
|
|
|
—
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2)
|
|
2020
|
|
> of 4.50% or
LIBOR plus 3.50% |
|
—
|
|
|
582.5
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2)
|
|
2020
|
|
> of 3.50% or
LIBOR plus 2.50% |
|
620.4
|
|
|
—
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2) (3)
|
|
2021
|
|
> of 5.00% or
LIBOR plus 4.00% |
|
—
|
|
|
1,444.2
|
|
||
|
First Lien Credit Facility - USD Term Loans
(2) (3)
|
|
2021
|
|
> of 4.00% or
LIBOR plus 3.00% |
|
1,121.2
|
|
|
—
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2)
|
|
2020
|
|
> of 4.25% or EURIBOR plus 3.25%
|
|
—
|
|
|
726.5
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2)
|
|
2020
|
|
> of 3.25% or EURIBOR plus 2.50%
|
|
694.3
|
|
|
—
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2) (3)
|
|
2021
|
|
> of 4.75% or EURIBOR plus 3.75%
|
|
—
|
|
|
450.7
|
|
||
|
First Lien Credit Facility - Euro Term Loans
(2) (3)
|
|
2021
|
|
> of 3.50% or EURIBOR plus 2.75%
|
|
716.0
|
|
|
—
|
|
||
|
Borrowings under the Revolving Credit Facility
|
|
|
|
LIBOR plus 3.00%
|
|
—
|
|
|
—
|
|
||
|
Borrowings under lines of credit
(4)
|
|
|
|
|
|
28.5
|
|
|
86.0
|
|
||
|
Capital leases and other
|
|
|
|
|
|
14.7
|
|
|
14.5
|
|
||
|
Total debt and capital lease obligations
|
|
|
|
|
|
5,479.5
|
|
|
5,239.0
|
|
||
|
Less: current installments of long-term debt and revolving credit facilities
|
|
|
|
|
|
38.9
|
|
|
116.1
|
|
||
|
Total long-term debt and capital lease obligations
|
|
|
|
|
|
$
|
5,440.6
|
|
|
$
|
5,122.9
|
|
|
(1)
|
Net of unamortized premium, discounts and debt issuance costs of
$35.5 million
and
$33.4 million
at
December 31, 2017
and
2016
, respectively. Weighted average effective interest rate of
6.53%
and
7.81%
at
December 31, 2017
and
2016
, respectively.
|
|
($ amounts in millions)
|
|
|
|
Long-Term Debt
|
|
Capital Leases
|
|
Total
|
||||||
|
2018
|
|
|
|
$
|
—
|
|
|
$
|
0.7
|
|
|
$
|
0.7
|
|
|
2019
|
|
|
|
—
|
|
|
0.6
|
|
|
0.6
|
|
|||
|
2020
|
|
|
|
1,330.8
|
|
|
0.5
|
|
|
1,331.3
|
|
|||
|
2021
|
|
(*)
|
|
1,854.4
|
|
|
0.5
|
|
|
1,854.9
|
|
|||
|
2022
|
|
|
|
1,100.0
|
|
|
0.4
|
|
|
1,100.4
|
|
|||
|
Thereafter
|
|
|
|
1,219.9
|
|
|
1.6
|
|
|
1,221.5
|
|
|||
|
Total
|
|
|
|
$
|
5,505.1
|
|
|
$
|
4.3
|
|
|
$
|
5,509.4
|
|
|
($ amounts in millions)
|
|
Balance before refinancing
|
|
Refinancing
|
|
Balance after refinancing
|
||||||
|
U.S. Dollar Tranche B-4 Term Loan due 2021
|
|
$
|
1,467.6
|
|
|
$
|
(1,467.6
|
)
|
|
$
|
—
|
|
|
U.S. Dollar Tranche B-6 Term Loan due 2021
|
|
—
|
|
|
1,231.0
|
|
|
1,231.0
|
|
|||
|
U.S. Dollar Tranche B-5 Term Loan due 2020
|
|
603.9
|
|
|
(603.9
|
)
|
|
—
|
|
|||
|
U.S. Dollar Tranche B-7 Term Loan due 2020
|
|
—
|
|
|
680.0
|
|
|
680.0
|
|
|||
|
Euro Tranche C-3 Term Loan due 2021
|
|
462.3
|
|
|
(462.3
|
)
|
|
—
|
|
|||
|
Euro Tranche C-5 Term Loan due 2021
|
|
—
|
|
|
697.5
|
|
|
697.5
|
|
|||
|
Euro Tranche C-4 Term Loan due 2020
|
|
814.0
|
|
|
(814.0
|
)
|
|
—
|
|
|||
|
Euro Tranche C-6 Term Loan due 2020
|
|
—
|
|
|
740.0
|
|
|
740.0
|
|
|||
|
Totals repriced first lien debt
|
|
$
|
3,347.8
|
|
|
$
|
0.7
|
|
|
$
|
3,348.5
|
|
|
($ amounts in millions)
|
|
|
|
December 31,
|
||||||
|
Derivatives not designated as hedging instruments:
|
|
Location on Condensed Consolidated Statement of Operations:
|
|
2017
|
|
2016
|
||||
|
Foreign exchange and metals contracts
|
|
Other (expense) income, net
|
|
$
|
(9.5
|
)
|
|
$
|
(12.5
|
)
|
|
|
|
December 31, 2017
|
|
December 31, 2016
|
||||||||||||
|
($ amounts in millions)
|
|
Asset
|
|
Liability
|
|
Asset
|
|
Liability
|
||||||||
|
Gross amounts
|
|
$
|
5.5
|
|
|
$
|
6.2
|
|
|
$
|
6.3
|
|
|
$
|
8.9
|
|
|
Gross amount subject to offset in master netting arrangements that are not offset
|
|
(1.0
|
)
|
|
(2.0
|
)
|
|
(2.5
|
)
|
|
(2.6
|
)
|
||||
|
Cash collateral paid
|
|
—
|
|
|
(0.4
|
)
|
|
—
|
|
|
(1.0
|
)
|
||||
|
Net
|
|
$
|
4.5
|
|
|
$
|
3.8
|
|
|
$
|
3.8
|
|
|
$
|
5.3
|
|
|
|
|
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
Balance sheet location
|
|
Classification
|
|
2017
|
|
2016
|
||||
|
Asset Category
|
|
|
|
|
|
|
|
|
||||
|
Foreign exchange and metals contracts not designated as hedging instruments
|
|
Other current assets
|
|
Level 2
|
|
5.5
|
|
|
8.5
|
|
||
|
Available for sale equity securities
|
|
Other assets
|
|
Level 1
|
|
3.7
|
|
|
5.1
|
|
||
|
Interest rate swaps designated as cash flow hedging instruments
|
|
Other assets
|
|
Level 2
|
|
3.4
|
|
|
—
|
|
||
|
Available for sale equity securities
|
|
Other assets
|
|
Level 2
|
|
0.6
|
|
|
0.6
|
|
||
|
Total
|
|
|
|
|
|
$
|
13.2
|
|
|
$
|
14.2
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Liability Category
|
|
|
|
|
|
|
|
|
||||
|
Interest rate swaps designated as cash flow hedging instruments
|
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
$
|
2.8
|
|
|
$
|
10.2
|
|
|
Foreign exchange and metals contracts not designated as hedging instruments
|
|
Accrued expenses and other liabilities
|
|
Level 2
|
|
7.3
|
|
|
10.7
|
|
||
|
Interest rate swaps designated as cash flow hedging instruments
|
|
Other liabilities
|
|
Level 2
|
|
0.8
|
|
|
—
|
|
||
|
Long-term contingent consideration
|
|
Contingent consideration
|
|
Level 3
|
|
79.2
|
|
|
75.8
|
|
||
|
Total
|
|
|
|
|
|
$
|
90.1
|
|
|
$
|
96.7
|
|
|
($ amounts in millions)
|
|
Foreign Currency Translation Adjustments
|
|
Pension and Post-retirement Plans
|
|
Unrealized Gain (Loss) on Available for Sale Securities
|
|
Derivative Financial Instrument Revaluation
|
|
Non-Controlling Interests
|
|
Accumulated Other Comprehensive (Loss) Income
|
||||||||||||
|
Balance at December 31, 2014
|
|
$
|
(122.2
|
)
|
|
$
|
(14.9
|
)
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
6.4
|
|
|
$
|
(130.6
|
)
|
|
Other comprehensive (loss) income before reclassifications, net
|
|
(777.1
|
)
|
|
(10.9
|
)
|
|
1.1
|
|
|
(8.1
|
)
|
|
40.0
|
|
|
(755.0
|
)
|
||||||
|
Reclassifications, pretax
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Tax benefit reclassified
|
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
||||||
|
Balance at December 31, 2015
|
|
(899.3
|
)
|
|
(26.3
|
)
|
|
1.2
|
|
|
(8.1
|
)
|
|
46.4
|
|
|
(886.1
|
)
|
||||||
|
Other comprehensive income (loss) before reclassifications, net
|
|
204.6
|
|
|
8.3
|
|
|
(0.8
|
)
|
|
(9.6
|
)
|
|
(2.0
|
)
|
|
200.5
|
|
||||||
|
Reclassifications, pretax
|
|
—
|
|
|
(0.8
|
)
|
|
—
|
|
|
11.9
|
|
|
—
|
|
|
11.1
|
|
||||||
|
Tax (benefit) expense reclassified
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Balance at December 31, 2016
|
|
(694.7
|
)
|
|
(18.8
|
)
|
|
0.4
|
|
|
(5.8
|
)
|
|
44.4
|
|
|
(674.5
|
)
|
||||||
|
Other comprehensive income (loss) before reclassifications, net
|
|
241.1
|
|
|
2.5
|
|
|
(2.2
|
)
|
|
(4.6
|
)
|
|
(3.6
|
)
|
|
233.2
|
|
||||||
|
Reclassifications, pretax
|
|
—
|
|
|
10.5
|
|
|
0.5
|
|
|
10.4
|
|
|
—
|
|
|
21.4
|
|
||||||
|
Tax (benefit) expense reclassified
|
|
—
|
|
|
(2.1
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(2.1
|
)
|
||||||
|
Balance at December 31, 2017
|
|
$
|
(453.6
|
)
|
|
$
|
(7.9
|
)
|
|
$
|
(1.3
|
)
|
|
$
|
—
|
|
|
$
|
40.8
|
|
|
$
|
(422.0
|
)
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions, except per share amounts)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
|
Numerator adjustments for diluted loss per share:
|
|
|
|
|
|
|
||||||
|
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
|
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
(32.9
|
)
|
|
—
|
|
|||
|
Remeasurement adjustment associated with the Preferred Series B redemption liability
|
|
—
|
|
|
5.0
|
|
|
—
|
|
|||
|
Loss allocated to PDH non-controlling interest
|
|
—
|
|
|
(5.9
|
)
|
|
—
|
|
|||
|
Net loss attributable to common stockholders for diluted loss per share
|
|
$
|
(296.2
|
)
|
|
$
|
(177.6
|
)
|
|
$
|
(308.6
|
)
|
|
|
|
|
|
|
|
|
||||||
|
Basic weighted average common stock outstanding
|
|
286.1
|
|
|
243.3
|
|
|
203.2
|
|
|||
|
Denominator adjustments for diluted loss per share:
|
|
|
|
|
|
|
||||||
|
Conversion related to the amendment of the Series B Convertible Preferred Stock - assumed at beginning of reporting period
|
|
—
|
|
|
15.3
|
|
|
—
|
|
|||
|
Settlement of preferred stock redemption liability - assumed at beginning of reporting period
|
|
—
|
|
|
5.7
|
|
|
—
|
|
|||
|
Conversion of PDH non-controlling interest
|
|
—
|
|
|
8.0
|
|
|
—
|
|
|||
|
Share adjustments
|
|
—
|
|
|
29.0
|
|
|
—
|
|
|||
|
Dilutive weighted average common stock outstanding
|
|
286.1
|
|
|
272.3
|
|
|
203.2
|
|
|||
|
|
|
|
|
|
|
|
||||||
|
Loss per share attributable to common stockholders:
|
|
|
|
|
|
|
|
|
|
|||
|
Basic
|
|
$
|
(1.04
|
)
|
|
$
|
(0.17
|
)
|
|
$
|
(1.52
|
)
|
|
Diluted
|
|
$
|
(1.04
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(1.52
|
)
|
|
|
|
|
|
|
|
|
||||||
|
Dividends per share paid to common stockholders
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
Year Ended December 31,
|
|||||||
|
(amounts in thousands)
|
|
2017
|
|
2016
|
|
2015
|
|||
|
Shares issuable for the contingent consideration
|
|
7,421
|
|
|
8,553
|
|
|
4,640
|
|
|
Shares issuable upon conversion of PDH Common Stock
|
|
5,967
|
|
|
—
|
|
|
8,318
|
|
|
Shares issuable upon conversion of Series A Preferred Stock
|
|
2,000
|
|
|
2,000
|
|
|
2,000
|
|
|
Shares issuable upon vesting of RSUs
|
|
842
|
|
|
147
|
|
|
74
|
|
|
Shares issuable upon vesting and exercise of stock options
|
|
51
|
|
|
—
|
|
|
55
|
|
|
Shares issuable under the ESPP
|
|
3
|
|
|
2
|
|
|
1
|
|
|
Shares issuable upon conversion of Series B Convertible Preferred Stock
|
|
—
|
|
|
—
|
|
|
19,443
|
|
|
Shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock
|
|
—
|
|
|
—
|
|
|
1,239
|
|
|
Total shares excluded
|
|
16,284
|
|
|
10,702
|
|
|
35,770
|
|
|
($ amounts in millions)
|
|
Operating Lease Commitments
|
||
|
Year ending December 31,
|
|
|
||
|
2018
|
|
$
|
33.0
|
|
|
2019
|
|
25.0
|
|
|
|
2020
|
|
19.6
|
|
|
|
2021
|
|
13.9
|
|
|
|
2022
|
|
12.1
|
|
|
|
Thereafter
|
|
28.9
|
|
|
|
Total
|
|
$
|
132.5
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Performance Solutions
|
|
$
|
23.5
|
|
|
$
|
25.0
|
|
|
$
|
6.9
|
|
|
Agricultural Solutions
|
|
7.3
|
|
|
6.1
|
|
|
18.4
|
|
|||
|
Total restructuring
|
|
$
|
30.8
|
|
|
$
|
31.1
|
|
|
$
|
25.3
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Cost of sales
|
|
$
|
0.9
|
|
|
$
|
0.9
|
|
|
$
|
6.3
|
|
|
Selling, technical, general and administrative
|
|
29.9
|
|
|
30.2
|
|
|
19.0
|
|
|||
|
Total restructuring
|
|
$
|
30.8
|
|
|
$
|
31.1
|
|
|
$
|
25.3
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Loss on debt extinguishments
|
|
$
|
(72.3
|
)
|
|
$
|
(11.3
|
)
|
|
$
|
—
|
|
|
Loss on derivative contracts
|
|
(9.5
|
)
|
|
(12.5
|
)
|
|
(74.0
|
)
|
|||
|
Non-cash change in fair value of preferred stock redemption liability
|
|
—
|
|
|
(5.0
|
)
|
|
—
|
|
|||
|
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
103.0
|
|
|
—
|
|
|||
|
Legal settlements
|
|
10.8
|
|
|
—
|
|
|
17.7
|
|
|||
|
Sale of intellectual property and product rights
|
|
2.2
|
|
|
4.4
|
|
|
6.1
|
|
|||
|
Other income, net
|
|
7.6
|
|
|
9.7
|
|
|
6.6
|
|
|||
|
Total
|
|
$
|
(61.2
|
)
|
|
$
|
88.3
|
|
|
$
|
(43.6
|
)
|
|
|
|
December 31,
|
||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
||||
|
Accrued customer rebates and sales incentives
|
|
$
|
127.7
|
|
|
$
|
120.7
|
|
|
Accrued salaries, wages and employee benefits
|
|
117.0
|
|
|
103.5
|
|
||
|
Accrued income taxes payable
|
|
73.1
|
|
|
82.5
|
|
||
|
Accrued interest
|
|
47.8
|
|
|
49.2
|
|
||
|
Other current liabilities
|
|
$
|
225.5
|
|
|
$
|
227.1
|
|
|
Total
|
|
$
|
591.1
|
|
|
$
|
583.0
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Net Sales:
|
|
|
|
|
|
|
||||||
|
Performance Solutions
|
|
$
|
1,878.6
|
|
|
$
|
1,770.1
|
|
|
$
|
800.8
|
|
|
Agricultural Solutions
|
|
1,897.3
|
|
|
1,815.8
|
|
|
1,741.5
|
|
|||
|
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
|
|||
|
Performance Solutions
|
|
$
|
155.0
|
|
|
$
|
156.5
|
|
|
$
|
80.0
|
|
|
Agricultural Solutions
|
|
199.2
|
|
|
185.8
|
|
|
171.0
|
|
|||
|
Total
|
|
$
|
354.2
|
|
|
$
|
342.3
|
|
|
$
|
251.0
|
|
|
Capital expenditures and product registrations:
|
|
|
|
|
|
|
|
|
|
|||
|
Performance Solutions
|
|
$
|
29.3
|
|
|
$
|
29.3
|
|
|
$
|
17.6
|
|
|
Agricultural Solutions
|
|
70.6
|
|
|
63.4
|
|
|
64.7
|
|
|||
|
Total
|
|
$
|
99.9
|
|
|
$
|
92.7
|
|
|
$
|
82.3
|
|
|
Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|||
|
Performance Solutions
|
|
$
|
432.7
|
|
|
$
|
401.3
|
|
|
$
|
224.3
|
|
|
Agricultural Solutions
|
|
388.2
|
|
|
368.2
|
|
|
343.4
|
|
|||
|
Total
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
($ amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Net loss attributable to common stockholders
|
|
$
|
(296.2
|
)
|
|
$
|
(40.8
|
)
|
|
$
|
(308.6
|
)
|
|
Add (subtract):
|
|
|
|
|
|
|
||||||
|
Gain on amendment of Series B Convertible Preferred Stock
|
|
—
|
|
|
(32.9
|
)
|
|
—
|
|
|||
|
Net income (loss) attributable to the non-controlling interests
|
|
0.6
|
|
|
(3.0
|
)
|
|
4.2
|
|
|||
|
Income tax expense
|
|
6.6
|
|
|
28.6
|
|
|
75.1
|
|
|||
|
Interest expense, net
|
|
341.6
|
|
|
375.7
|
|
|
213.9
|
|
|||
|
Depreciation expense
|
|
78.3
|
|
|
75.0
|
|
|
48.9
|
|
|||
|
Amortization expense
|
|
275.9
|
|
|
267.3
|
|
|
202.1
|
|
|||
|
EBITDA
|
|
406.8
|
|
|
669.9
|
|
|
235.6
|
|
|||
|
Adjustments to reconcile to Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|||
|
Restructuring expense
|
|
30.8
|
|
|
31.1
|
|
|
25.3
|
|
|||
|
Amortization of inventory step-up
|
|
—
|
|
|
11.7
|
|
|
76.5
|
|
|||
|
Acquisition and integration costs
|
|
4.8
|
|
|
33.4
|
|
|
122.4
|
|
|||
|
Non-cash change in fair value of contingent consideration
|
|
3.4
|
|
|
5.1
|
|
|
6.8
|
|
|||
|
Legal settlements
|
|
(10.8
|
)
|
|
(2.8
|
)
|
|
(16.0
|
)
|
|||
|
Foreign exchange loss on foreign denominated external and internal long-term debt
|
|
102.5
|
|
|
33.9
|
|
|
46.4
|
|
|||
|
Debt refinancing costs
|
|
83.2
|
|
|
19.7
|
|
|
—
|
|
|||
|
Fair value loss on foreign exchange forward contract
|
|
—
|
|
|
—
|
|
|
73.7
|
|
|||
|
Goodwill impairment
|
|
160.0
|
|
|
46.6
|
|
|
—
|
|
|||
|
Gain on settlement agreement related to Series B Convertible Preferred Stock
|
|
—
|
|
|
(103.0
|
)
|
|
—
|
|
|||
|
Non-cash change in fair value of preferred stock redemption liability
|
|
—
|
|
|
5.0
|
|
|
—
|
|
|||
|
Costs related to Proposed Separation
|
|
12.1
|
|
|
—
|
|
|
—
|
|
|||
|
Pension plan settlement and curtailment
|
|
10.5
|
|
|
1.8
|
|
|
—
|
|
|||
|
Other, net
|
|
17.6
|
|
|
17.1
|
|
|
(3.0
|
)
|
|||
|
Adjusted EBITDA
|
|
$
|
820.9
|
|
|
$
|
769.5
|
|
|
$
|
567.7
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
United States
|
|
$
|
654.7
|
|
|
$
|
725.4
|
|
|
$
|
474.6
|
|
|
Brazil
|
|
476.7
|
|
|
463.0
|
|
|
380.6
|
|
|||
|
Other countries
|
|
2,644.5
|
|
|
2,397.5
|
|
|
1,687.1
|
|
|||
|
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
|
|
December 31,
|
||||||
|
(amounts in millions)
|
|
2017
|
|
2016
|
||||
|
United States
|
|
$
|
122.2
|
|
|
$
|
137.4
|
|
|
France
|
|
48.2
|
|
|
47.2
|
|
||
|
China
|
|
42.0
|
|
|
47.3
|
|
||
|
Other countries
|
|
239.9
|
|
|
228.6
|
|
||
|
Total
|
|
$
|
452.3
|
|
|
$
|
460.5
|
|
|
|
|
Year Ended December 31,
|
||||||||||
|
(amounts in millions)
|
|
2017
|
|
2016
|
|
2015
|
||||||
|
Performance Solutions
|
|
|
|
|
|
|
||||||
|
Assembly Solutions
|
|
$
|
629.7
|
|
|
$
|
554.5
|
|
|
$
|
41.1
|
|
|
Electronics Solutions
|
|
538.7
|
|
|
525.9
|
|
|
198.8
|
|
|||
|
Industrial Solutions
|
|
482.2
|
|
|
445.0
|
|
|
287.8
|
|
|||
|
Graphics Solutions
|
|
153.4
|
|
|
171.8
|
|
|
173.9
|
|
|||
|
Offshore Solutions
|
|
74.6
|
|
|
72.9
|
|
|
99.2
|
|
|||
|
Performance Solutions sales
|
|
1,878.6
|
|
|
1,770.1
|
|
|
800.8
|
|
|||
|
Agricultural Solutions
|
|
|
|
|
|
|
||||||
|
Agricultural Solutions
|
|
1,873.9
|
|
|
1,794.3
|
|
|
1,727.9
|
|
|||
|
Animal Health
|
|
23.4
|
|
|
21.5
|
|
|
13.6
|
|
|||
|
Agricultural Solutions
|
|
1,897.3
|
|
|
1,815.8
|
|
|
1,741.5
|
|
|||
|
Total
|
|
$
|
3,775.9
|
|
|
$
|
3,585.9
|
|
|
$
|
2,542.3
|
|
|
|
|
2017
|
||||||||||||||
|
($ amounts in millions, except per share amounts)
|
|
First
Quarter
|
|
Second
Quarter
|
|
Third
Quarter
|
|
Fourth
Quarter
|
||||||||
|
Selected Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
||||||||
|
Net sales
|
|
$
|
861.8
|
|
|
$
|
941.1
|
|
|
$
|
904.3
|
|
|
$
|
1,068.7
|
|
|
Gross profit
|
|
378.4
|
|
|
399.9
|
|
|
371.1
|
|
|
439.6
|
|
||||
|
Net loss attributable to stockholders
|
|
(24.4
|
)
|
|
(61.1
|
)
|
|
(69.2
|
)
|
|
(141.5
|
)
|
||||
|
Net loss attributable to common stockholders
|
|
(24.4
|
)
|
|
(61.1
|
)
|
|
(69.2
|
)
|
|
(141.5
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Loss per share
|
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
|
$
|
(0.09
|
)
|
|
$
|
(0.21
|
)
|
|
$
|
(0.24
|
)
|
|
$
|
(0.49
|
)
|
|
Diluted
|
|
(0.09
|
)
|
|
(0.21
|
)
|
|
(0.24
|
)
|
|
(0.49
|
)
|
||||
|
|
|
2016
|
||||||||||||||
|
($ amounts in millions, except per share amounts)
|
|
First
Quarter
|
|
Second
Quarter
|
|
Third
Quarter
|
|
Fourth
Quarter
|
||||||||
|
Selected Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
||||||||
|
Net sales
|
|
$
|
823.8
|
|
|
$
|
921.6
|
|
|
$
|
890.5
|
|
|
$
|
950.0
|
|
|
Gross profit
|
|
356.0
|
|
|
380.6
|
|
|
375.1
|
|
|
396.0
|
|
||||
|
Net (loss) income attributable to stockholders
|
|
(134.8
|
)
|
|
(8.8
|
)
|
|
71.8
|
|
|
(1.9
|
)
|
||||
|
Net (loss) income attributable to common stockholders
|
|
(134.8
|
)
|
|
(8.8
|
)
|
|
104.7
|
|
|
(1.9
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
(Loss) earnings per share
|
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
|
$
|
(0.59
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
0.45
|
|
|
$
|
(0.01
|
)
|
|
Diluted
|
|
(0.59
|
)
|
|
(0.04
|
)
|
|
(0.15
|
)
|
|
(0.01
|
)
|
||||
|
(amounts in millions)
|
|
Balance at
beginning of
period
|
|
Charges to
costs and
expense
|
|
Deductions
from
reserves and other
(1)
|
|
Balance at
end of period
|
||||||||
|
Reserves against accounts receivable:
|
|
|
|
|
|
|
|
|
||||||||
|
2017
|
|
$
|
(36.7
|
)
|
|
$
|
(10.0
|
)
|
|
$
|
(0.9
|
)
|
|
$
|
(47.6
|
)
|
|
2016
|
|
(14.4
|
)
|
|
(19.0
|
)
|
|
(3.3
|
)
|
|
(36.7
|
)
|
||||
|
2015
|
|
(9.6
|
)
|
|
(9.2
|
)
|
|
4.4
|
|
|
(14.4
|
)
|
||||
|
(1)
|
Other activity consists primarily of currency translation effects.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|